**Cerebral Hypoperfusion and Glucose Hypometabolism: Key Pathophysiological
Modulators Promote Neurodegeneration, Cognitive Impairment,
and Alzheimer's Disease**

Mak Adam Daulatzai

Sleep Disorders Group, EEE Dept/MSE
The University of Melbourne,
Parkville, Victoria 3010, Australia

Correspondence should be addressed to:

Mak Adam Daulatzai, M.Sc., Ph.D., M.D., Ph.D.

Senior Medical Research Fellow

EEE Dept, MSE

The University of Melbourne

Parkville, Victoria 3010, Australia

Email: makdaulatzai@gmail.com

RUNNING TITLE: Cerebral hypoperfusion and Glucose hypometabolism promote cognitive dysfunction

KEYWORDS: Alzheimer's disease; Cerebral hypoperfusion; Glucose hypometabolism; Cerebral Amyloid Angiopathy; Blood–Brain Barrier Dysfunction; Brain atrophy

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version record](#). Please cite this article as [doi:10.1002/jnr.23777](https://doi.org/10.1002/jnr.23777).

Article Outline**Abstract****1. Introduction****2. Conditions That Promote Cerebral Hypoperfusion and Glucose Hypometabolism**

- 2.1 Aging
- 2.2 Intermittent Hypoxia/Obstructive Sleep Apnea
- 2.3 Hypertension
- 2.4 Obesity/ Metabolic syndrome
- 2.5 Vitamin B12/Folate Deficiency
- 2.6 Diabetes Mellitus
- 2.7 Depression
- 2.8 Traumatic Brain Injury

3. Framework Highlighting Pathological Ramifications and Cognitive Vulnerability Owing to Chronic hypoperfusion and hypometabolism

- 3.1 Diverse Comorbid Conditions Trigger Vascular Pathology
- 3.2 Cerebral Amyloid Angiopathy (CAA)
- 3.3 Blood–Brain Barrier (BBB) Dysfunction
 - 3.3.1 Disruption of Glucose Uptake Impairs BBB Integrity
 - 3.3.2 BBB Disruption Promotes Neuronal Loss
 - 3.3.3 Hypoperfusion and Neuronal Death
- 3.4 Cerebral Hypometabolism
- 3.5 Brain Atrophy: A Defining Impairment in Multiple Risk Factors
 - 3.5.1 Aging
 - 3.5.2 Obesity
 - 3.5.3 Homocysteine
 - 3.5.4 Sleep Deprivation
 - 3.5.5 Chronic Alcohol Abuse
- 3.6 Elderly and Cognitive Impairment

4. Cerebral Hypoperfusion: Therapeutic Approach

- 4.1 Reperfusion-Rehabilitation Approach
- 4.2 Pharmacological Approach
- 4.3 Nutraceutical Approach

5. Concluding Remarks**References**

Abbreviation

A β - amyloid beta

AD - Alzheimer's disease

BBB - blood-brain barrier

BFVs - Blood flow velocities

BOLD - blood-oxygen level dependent

BP - High blood pressure, hypertension

CAA - cerebral amyloid angiopathy

CBFV - Changes in CBF velocity

CSD - Chronic sleep deprivation

CMR_{glc} - cerebral metabolic rate of glucose

CMRO₂ - cerebral metabolic rate of oxygen

CV - Cerebrovascular

CRP - C-reactive protein

DMN - default-mode network

EC - entorhinal cortex

fMRI - Functional MRI

FDG - 2-[18F]fluoro-2-Deoxy-D-glucose

GluRs - glutamate receptors

HbA(1c) - Glycosylated haemoglobin

Hhcy - hyperhomocysteinemia

HIF-1 α - Hypoxia-inducible factor 1-alpha

ICAM-1 - Intercellular adhesion molecule 1

LTP - long-term potentiation

MCP-1 - monocyte chemoattractant protein

MetS - metabolic syndrome

MDD - major depressive disorder

MMP - matrix metalloproteinase

MCI - mild cognitive impairment

MMSE - Mini-Mental State Examination (MMSE)

MRS - magnetic resonance spectroscopy

NO - nitric oxide

NOS - nitric oxide synthase

NFT - neurofibrillary tangles

PCC - posterior cingulate cortex

PET - positron emission tomography

PIB - Pittsburgh compound B

rCBF - regional cerebral blood flow

ROS - reactive oxidative stress

SPECT - Single photon emission computed tomography

SPs - senile plaques

T2DM - type 2 diabetes mellitus

TBM - tensor-based morphometry

TGF- β 1 - transforming growth factor- β 1

VaD - vascular dementia ()

VCAM-1 - vascular cell adhesion molecule 1

WMH - white matter hyperintensities

Significance

Aging, hypertension, diabetes, hypoxia/OSA, obesity, vitamin B12/folate deficiency, depression, and traumatic brain injury – synergistically promote diverse pathological mechanisms including cerebral hypoperfusion and glucose hypometabolism. These risk factors trigger neuroinflammation and oxidative-nitrosative stress that in turn decrease nitric oxide, and enhance endothelin, Amyloid beta deposition, cerebral amyloid angiopathy, and blood-brain-barrier disruption. Proinflammatory cytokines, endothelin-1, and oxidative-nitrosative stress trigger several pathological feed-forward and feed-back loops. The above upstream factors persist in the brain for decades upregulating amyloid and tau, before the cognitive decline. The above cascades lead to neuronal Ca^{2+} increase, neurodegeneration, cognitive/memory decline, and AD. However, strategies are available to attenuate cerebral hypoperfusion and glucose hypometabolism and ameliorate cognitive decline.

Abstract

Alzheimer's disease (AD) is the leading cause of dementia among the elderly. There is significant evidence that pathways involving inflammation and oxidative-nitrosative stress (ONS) play a key pathophysiological role in promoting cognitive dysfunction. Several comorbid conditions including aging, hypoxia/OSA, hypertension, obesity, vitamin B12/folate deficiency, diabetes, depression, and traumatic brain injury – promote diverse pathological mechanisms. These include inflammation, ONS, hypoperfusion, and hypometabolism in the brain. In AD, chronic cerebral hypoperfusion and glucose hypometabolism precede decades before the cognitive decline. The above comorbid disease conditions may share and synergistically activate the above pathophysiological pathways. Inflammation upregulates cerebrovascular pathology through proinflammatory cytokines, endothelin-1, and nitric oxide (NO). Inflammation-triggered ONS promotes long-term damage involving fatty acids, proteins, DNA, and mitochondria; these amplify and perpetuate several feed-forward and feedback pathological loops. The latter includes dysfunctional energy metabolism (compromised mitochondrial ATP production), amyloid beta generation, endothelial dysfunction, and blood-brain-barrier disruption. These lead to decreased cerebral blood flow and chronic cerebral hypoperfusion- that would modulate metabolic dysfunction and neurodegeneration. In essence, hypoperfusion deprives the brain with its two paramount trophic substances, *viz.* Oxygen and nutrients. Consequently, the brain suffers from synaptic dysfunction and neuronal degeneration/loss leading to both gray and white matter atrophy, cognitive dysfunction, and AD. This paper underscores the importance of treating the above mentioned comorbid disease conditions to attenuate inflammation and ONS and ameliorate decreased cerebral blood flow and hypometabolism. Additionally, several strategies are described here to control chronic hypoperfusion of the brain and enhance cognition.

Accepted

1. Introduction

Alzheimer's disease (AD) is a sporadic late-onset disease; its prevalence increases with the age of 65 years onwards. Since we are living longer, there is a stark shift in the epidemiology of age-related diseases including an escalating prevalence of AD and vascular dementia (VaD) (Whitehouse et al., 1997). Approximately 5.2 million Americans have late-onset AD, and about 200,000 people younger than 65 years suffer from the early-onset AD (Alzheimer's Association, 2014). As per projections, the AD risk may double every five years (Takeda et al., 2008), and by mid-century, the number of AD patients in the United States may grow to about 9 million. AD adds a massive financial burden, and \$214 billion are estimated to be the health care cost in 2014 (Alzheimer's Association, 2014).

AD patients suffer from the progressive and gradual decline in memory and cognitive functions. While the etiology of the late-onset AD is largely unknown, familial early-onset AD is associated with gene mutations. It has been emphasized in recent years that environmental factors and epigenetic alterations may play a significant role in the neuropathogenesis of AD (Daulatzai, 2013b; 2014; 2015a; 2015b). Indeed, aging is an important risk factor for upregulation of gene expression related to inflammation and apoptosis in several age-related diseases. Mitochondrial dysfunction with resulting reactive oxygen species (ROS) generation is known to accompany aging (Daiber et al., 2015; Wu et al., 2015). Moreover, aging correlates with genetic and epigenetic perturbations and telomere attrition (Aviv et al., 2002; Blackburn et al., 2015).

Progressive atrophy, degeneration, and loss of neurons (referred here as neurodegeneration) are characteristic features of several neurodegenerative diseases. These include AD, Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS), Creutzfeldt-Jakob disease, and Huntington disease. The most salient risk factor for developing neurodegenerative diseases, in general, and late-onset AD, in particular, is aging. The characteristic visible neuropathological lesions in AD are 1. senile plaques (SPs) formed by amyloid beta ($A\beta$) and located outside neurons, and 2. neurofibrillary tangles (NFT) comprised of hyperphosphorylated tau (i.e. phospho-tau) are located within neurons (Su et al., 1996; Zhao et al., 2010). According to the amyloid cascade hypothesis, $A\beta$ is the noxious agent that triggers angiopathy, synaptopathy, glial (including microglial and astrocytic) activation-related inflammatory and reactive oxidative stress (ROS) responses, tau hyperphosphorylation (owing to altered activities of relevant kinases and phosphatases), and neuronal death (De Felice et al., 2007).

According to Tau hypothesis, phospho-tau accumulation, and the neurofibrillary degeneration occurs in neurons. The paired helical filaments in NFTs induce abnormal cellular metabolism and cause neuronal death. NFTs, therefore, are intimately associated with memory and cognitive dysfunctions (Goedert, 1993; Wes et al., 2014).

The intracellular endoplasmic reticulum (ER) is a reticular membrane network (Baumann and Walz, 2001) that performs several vital functions. These include: (i) protein folding, (ii) maintenance of cellular calcium, (iii) synthesis of lipids and sterols, and (iv) regulation of cellular homeostasis (Baumann and Walz, 2001; Gorchach et al., 2006; Schroder and Kaufman, 2005; Bernales et al., 2006; Ron and Walter, 2007; Kim et al., 2008).

According to ER stress hypothesis, ER stress and activated unfolded protein response (UPR) signaling are present in AD (Hoozemans et al., 2009) as well as other chronic neurodegenerative conditions (Lindholm et al., 2006; Paschen and Mengesdorf, 2005; Matus et al., 2008; Kanekura et al., 2009; Scheper and Hoozemans, 2009). Importantly, diverse conditions such as cerebral ischemia and viral infections can also induce ER stress and trigger the UPR signaling (Hoozemans et al., 2009; DeGracia and Montie, 2004; Williams and Lipkin, 2009). Indeed, ER stress of neurons is linked to the inflammatory activation that may promote AD pathogenesis (Salminen et al., 2009).

Data from the brains of those with advanced age and AD have consistently shown damage or abnormalities in basal forebrain projections to the cortex; this correlates with cognitive decline. Hence, the "cholinergic hypothesis" postulates that a loss of cholinergic function in the brain contributes to the cognitive decline associated with advanced age and AD (Bartus, 2000; Schliebs and Arendt, 2011; Shen and WU, 2015). Therefore, to date, the mainstay of preventive treatment of AD is acetylcholinesterase inhibitors (Hosoi et al., 2015).

Brain's viability and its myriad of functions critically rely on the continuous supply of energy substrates and oxygen via blood flow. During functional activation – when there is an increased energy demand, regional cerebral blood flow (rCBF) is locally adjusted in the brain to meet this demand. This is achieved by regulating microvessel diameter and concomitant dilatation of upstream arteries and arterioles (that supply blood to the capillary bed). This physiological neurovascular coupling is essential regarding rCBF changes being linked to neuronal activity, temporally and spatially (Feuerstein et al., 2014; Vanzetta et al., 2008). Any sustained reduction in rCBF, therefore, may reduce tissue function and cause regional cerebral damage. 2-[18F]fluoro-2-Deoxy-D-glucose (FDG) positron emission tomography (PET) (FDG-PET) is used to measure the cerebral metabolic rate of glucose (CMRglc) as a surrogate for neuronal activity. FDG-PET shows in vivo cerebral glucose utilization (CGU) and changes in brain metabolism. The term upstream refers to arterial branches the blood flows through before reaching the metabolite exchange (glucose, O₂/CO₂) site. Under pathologic conditions, the upstream blood supply limitation could be the proximal (involving arterioles or pial arteries) or distal (involving the carotid artery and heart).

Cortical spreading depolarizations (CSD - a self-propagating wave of membrane/tissue depolarization) is associated with significant changes in tissue metabolism and blood flow (Ayata et al., 2006, Feuerstein et al., 2010, Lauritzen, 1987; Piilgaard et al., 2009). CSD can arise in the normal brain; it can also arise after brain injury (Kumagai et al., 2010, Shin et al., 2006; Strong et al., 2007) and clinically (Dohmen et al., 2008, Fabricius et al., 2006, Hartings et al., 2011; Lauritzen et al., 2011). As such, CSD is a phenomenon that correlates with the normal or reduced rCBF response (via upstream blood supply) to energy needs in health and disease. The close regional coupling of rCBF, therefore, involves both cerebral metabolic rate of oxygen (CMRO₂) and CMRglc (Powers et al., 2011). Neurovascular coupling (i.e. functional hyperemia) involves communication between neurons, astrocytes and cerebral vessels and this neurovascular unit adjusts blood supply for energy and oxygen needs of activated neurons (Lecrux and Hamel, 2011). Astrocytes cover the surface of intraparenchymal capillaries through their processes, suggesting that they may participate in glucose uptake. Other astrocytic processes wrap around synapses – the sites for receptors and reuptake of

neurotransmitters. There are specific glutamate transporters on the astrocytes, and glutamate stimulates glucose uptake into these cells (Magistretti and Pellerin, 1999).

A growing body of evidence emphasizes an association between vascular risk factors and Cognitive decline (Dickstein et al., 2010; Murray et al., 2011; Wang et al., 2014). Further, sex/gender is considered to play a pivotal role in the susceptibility for developing dementia induced by cardiovascular risk factors (Azad et al., 2007; Rosvall et al. 2009; Dufouil et al., 2014; Chêne et al., 2015). This interrelationship is important in understanding etio-pathophysiological mechanisms and the impact of vascular pathology in promoting neuropathology (*i.e.* plaque and tangle pathology) (Yarchoan et al., 2012). The underlying neuropathology may persist for decades before clinical diagnosis of AD. This paper is focused on the significance of chronic hypoperfusion-related pathophysiological signaling. The latter may upregulate several pathological mechanisms including endothelial dysfunction, glucose dyshomeostasis, inflammation, oxidative stress, and neurotoxicity. These trigger memory and cognitive dysfunction - before frank AD. This paper underscores significant evidence relevant to AD and emphasizes a link between the two major upstream pathogenetic factors and neuronal dysfunction and degeneration. The triggering of cognitive/memory dysfunction and AD, therefore, is posited to be a function of chronic hypoperfusion and glucose hypometabolism. Readers may find some early reviews on hypoperfusion, oxidative stress, and neuroinflammation interesting (de la Torre, 2012; Kim et al., 2012; Liu and Zhang, 2012).

2. Conditions That Promote Hypoperfusion

Various factors including older age, hypertension, hypercholesterolemia, diabetes, obesity, atherosclerosis, and cardiac diseases have been shown to enhance vascular risk and facilitate onset and progression of cognitive impairment (Debette et al., 2011; Kalaria, 2010; Murray et al., 2011; Rodrigue, 2013; see Table 1). Hence, identification and attenuation of these vascular risk factors in midlife must encompass an essential strategy to thwart the onset and progression of cognitive decline in advanced age.

2.1. Aging

Aging is an important risk factor for several age-related diseases and upregulation of gene expression related to inflammation and apoptosis. Aging is also correlated with genetic and epigenetic perturbations, telomere attrition (see above), mitochondrial dysfunction, and ROS increase (see below). An interrelationship has been emphasized between unhealthy diet, dysfunctional breathing, sleep restriction, and excess consumption of alcohol - and neuropathogenesis of cognitive dysfunction (Daulatzai, 2015b). AD, therefore, is recognized to arise from multifocal and multi-factorial mechanisms (Fig. 1.). The latter promote potentially deleterious downstream factors including amyloid and tau increase, mitochondrial dysfunction, synaptic injury/loss, and eventual neuronal degeneration and loss (Daulatzai, 2015a-2015d).

Two important indices of healthy brain aging are rCBF and CMRO₂. A PET study (in 66 healthy volunteers aged 21 to 81 years) found that the magnitudes of CBF and CMRO₂ declines in large areas of the cerebral cortex (Aanerud et al., 2012). Recently, perfusion deficit in the brain of cognitively normal older adults has been documented in the inferior parietal lobules (Okonkwo et al., 2014). Some possible reasons may be that aging is inevitably accompanied by vascular pathology (Bouras et al., 2006; Jeynes and Provias, 2006). The

latter may include cortical microinfarcts (Kövari et al., 2004; 2007), gray matter lacunes (Gold et al., 2005), and irreversible endothelial dysfunction (Hallam et al., 2010; Thal et al., 2009). Vascular pathological burden as hypoperfusion and neurodegeneration both precedes and parallels cognitive decline (Giannakopoulos et al., 2007; Jellinger, 2002; Kalaria et al., 1993; Koike et al., 2011). NFT were common in tau-positive neurons in the hippocampus from non-demented elderly persons (Takayama et al., 2002). In the elderly without dementia but memory dysfunction, cerebral circulatory/vascular abnormalities, and deleterious metabolic and functional impact may contribute to mild cognitive impairment (MCI) (Beckmann et al., 2003; Bennett et al., 2005; Okonkwo et al., 2014).

2.2 Intermittent Hypoxia/Obstructive Sleep Apnea

There are marked changes in cerebrovascular control during sleep disordered breathing notably Obstructive Sleep Apnea (OSA); this suggests that the cerebral circulation may be vulnerable to intermittent hypoxia (fig. 1.). Changes in CBF velocity (CBFV) and vascular compliance were evaluated (using transcranial Doppler sonography and cerebral pulse transit time) in patients with severe OSA. CBFV reactivity was significantly diminished in dysfunctional respiratory periods. CBF hyporeactivity was evident as a loss of vasoreactivity and increased arterial stiffness (Foster et al., 2007; Furtner et al., 2009). Further, a reduction in CBF occurs during Non-REM sleep despite a relative hypercapnia state (Baril et al., 2015; Corfield and Meadows, 2006). Patients with severe OSA (compared to controls) showed reduced CBF in the left parietal lobules, precentral gyrus, bilateral postcentral gyri, and right precuneus (Baril et al., 2015). Hence, vascular impairment in these AD-related important brain areas could result in neurodegenerative processes, neuronal dysfunction, and cognitive deficits (Fig.1.).

There is a close correlation between mean arterial pressure and CBFV. Thus, cerebral perfusion pressure prevents cerebral ischemia. Cerebrovascular autoregulation counteracts physiological fluctuations and maintains perfusion pressure. However, cerebral hypoperfusion may occur when there are a systemic hemodynamic failure and chronic dysfunctional cerebrovascular autoregulation. However, cerebral autoregulation is inadequate from rapid pressure changes in OSA (Bålfors and Franklin, 1994), and is, therefore, unable to protect the brain. Nocturnal apneas are associated with profound changes in CBF. Normally, vaso-neuronal coupling occurs owing to CBFV variations during neuronal stimulation (Daffertshofer and Hennerici, 1995). However, there is significant neuronal dysfunction in OSA patients (Daulatzai, 2015d; also see below) rendering vaso-neuronal coupling sub-optimal and CBFV insufficient. OSA patients develop decreased CBF velocity and delayed cerebrovascular compensatory response owing to sustained alterations in blood pressure. The above-mentioned increase the risk of cerebral ischemia during OSA (Daulatzai, 2013a; 2015b; Urbano et al., 2008). Apnea-induced hypoxemia in conjunction with reduced CBF (nocturnal and awake) would sustain cerebral hypoperfusion in OSA patients (Daulatzai, 2012; 2013a; 2013b; 2015a; 2015b; Foster et al., 2007).

2.3. Hypertension

Various epidemiological studies link Hypertension to AD. Hypertension leads to changes in blood vessel wall in the brain; this may upregulate hypoperfusion and ischemia thus promoting AD neuropathogenesis (Hughes et al., 2015). There are epidemiological data that show a relationship between high blood pressure (BP) and cognitive dysfunction and dementia. The relationship between hypertension and the prevalence of AD/dementia

have been shown in cross-sectional studies; indeed, longitudinal studies have suggested that high BP in midlife is associated with a higher incidence of AD in later life (Launer et al., 2000). A recent arterial spin labeling study has documented that individuals with hypertension have reduced temporal and occipital brain perfusion as well as decreased total and regional cortical thickness (compared with controls without hypertension) (Alosco et al., 2014). The meta-analysis also found that high BP leads to brain volume reduction, including the hippocampus (Beauchet et al., 2013). The synergistic effect of high BP and type 2 diabetes mellitus (T2DM) has a significant impact on hypoperfusion and cortical thickness (CThk). The latter was evident in the right lingual gyrus, posterior cingulate, precuneus, superior and middle frontal, and middle and inferior temporal regions (Tchistiakova et al., 2014). The above pathology and cognitive decline are inter-linked (Alosco et al., 2013).

Arterial spin-labeling MR imaging studies in the MCI patients (relative to controls) showed significant regional hypoperfusion in the right inferior parietal lobe. Further, the AD patients (relative to controls) showed significant regional hypoperfusion in several regions including right and left inferior parietal cortex extending, bilateral posterior cingulate gyri, and bilateral superior and middle frontal gyri (Johnson et al., 2005). After accounting for underlying cortical gray matter atrophy, the hypoperfusion persisted in the right inferior parietal lobe, bilateral posterior cingulate gyri, and right and left middle frontal gyri (Johnson et al., 2005).

Two important pathologies *i.e.* atherosclerosis and impaired cerebrovascular autoregulation are caused by chronic hypertension (Duron and Hanon, 2008; Kennelly et al., 2009; Qiu et al., 2005). In the Honolulu-Asia Aging study, 3605 Japanese-American men were followed prospectively over 26 years (1965-1991). The study found that high Systolic BP in midlife has a stronger adverse effect on cognitive function in APOE- positive persons (Peila et al., 2001). This particular study also found that elevated BP in midlife was associated with brain atrophy and greater numbers of amyloid plaques in both neocortex and hippocampus. However, elevated diastolic BP was associated with extensive NFT in the hippocampus (Petrovitch et al., 2000). Further, the A β -related pathological risk, *e.g.* of cerebral amyloid angiopathy (CAA), was found to be higher when BP was higher (Shah et al., 2012). This indicated that hypertension compromises vascular integrity, leads to CAA, and impairs A β clearance from the brain (Shah et al., 2012).

Functional MRI (fMRI) was performed in 541 women and men with mean age 50.4 years. Cerebrovascular reactivity (CVR) was quantified as the percentage change in blood-oxygen level dependent (BOLD) signal. Mean CVR was calculated for brain regions associated with the default-mode network (DMN) - a network implicated in AD (Haight et al., 2015). The study found that reduced CVR may represent diminished vascular functionality for the DMN for individuals with prehypertension/hypertension in mid-life (Haight et al., 2015). In a recent study on elderly patients with hypertension, a quantitative analysis of FDG-PET was conducted in the brain with an aim to characterize any MCI-like hypometabolic pattern. The study, although on a small number of patients, did find an MCI-like hypometabolic pattern in elderly hypertensives (Van Der Gucht et al., 2015). Indeed, hypertension was significantly associated with subjective memory impairment in older adults (Chen et al., 2014).

The relationship between severe OSA and the possible development of systemic hypertension (see below) is well established (Foster et al., 2009; Morrell et al. 2000, Nieto et al. 2000; Peppard et al. 2000). Indeed, patients with severe OSA may have increased the incidence of cardiovascular and cerebrovascular disease, and evidence

of structural cerebral lesions (Almendros et al., 2011; Foster et al., 2009). Epidemiologically, patients with severe OSA may have the risk of stroke (Arzt et al. 2005; Foster et al., 2009; Yaggi et al. 2005). Further, hypertension is a risk factor for MI, CVD, stroke, ischemic white matter hyperintensities (WMH), and silent infarcts. Indeed, there would be synergistic vascular insults (Kerber et al., 2006) since hypertension is linked to other risk factors such as T2DM, obesity, and hypercholesterolemia (Allan et al., 2015, Firkbank et al., 2007, Kovacic and Fuster, 2012; Skoog and Gustafson, 2003; 2006). These risk factors mentioned above have been related to AD, and an extensive literature exists on this. It is noteworthy that hypotension in late-life is also associated with an increased risk of AD (Mehrabian et al., 2010; Sambati et al., 2014). A recent experimental study on a mouse model of AD (TgSwDI) induced chronic hypertension and studied its effects after six months. Chronic hypertension promoted 1. vascular inflammation, 2. microvascular A β deposition, 3. BBB disruption, 4. pericyte loss, and 5. cognitive deficits (Kruyer et al., 2015). The Aged hypertensive mice (25 months old) (compared to 3 months old younger mice) showed increases in the APP-binding proteins in the hippocampus (Csiszar et al., 2013).

2.4. Obesity/ Metabolic Syndrome

About a third of U.S. adults have the metabolic syndrome (MetS) - and about one-sixth of 60 and older have MetS. Indeed, the incidence of MetS increases in the older adults (Ford et al., 2002). Several risk factors constitute MetS; these include abdominal obesity, hypertension, dyslipidemia, and glucose/insulin dysregulation. MetS is linked to diabetes, cardiovascular disease (CVD), and dementia. 65 years old obese patients without a clinical history of cognitive impairment showed high levels of tau and A β precursor protein expression, in some cases comparable to AD. AD-type changes in the obese (Compared to non-obese) may be due to comorbid diseases *viz.* Congestive heart failure, OSA, and hyperlipidemia (Mark, 2009). Mean gray matter CBF is about 15% lower in MetS (compared to controls); this may mediate the lower memory function noted in MetS (Birdsill et al., 2013). A significant increase in plasma Intercellular adhesion molecule 1 (ICAM-1), IL-8, and neutrophils occurs in the obese (relative to healthy subjects) (Carpagnano et al., 2010). MetS patients have significant inflammation, and this impacts cognition and memory. Indeed, individuals having both MetS and high inflammation possess a higher probability of memory and cognitive decline (Dik et al., 2007; Misiak et al., 2012; Yaffe et al., 2004). An Italian Longitudinal Study on Aging followed MCI patients with MetS (over 3.5 years) - an increased incidence of dementia was found in this population (Solfrizzi et al., 2011). Obesity per se is a recognized cause of cardiovascular pathologies (Alpert, 2001; Kalogeropoulos et al., 2010; Massie, 2002). Synergistic action of cerebral hypoperfusion and obesity is implicated in cognitive dysfunction in persons with heart pathology (Alosco et al., 2012; 2014). Indeed, this is further enhanced in individuals with, MetS, T2DM, and pathological heart issues, reflected in their lower volume of the cortical brain and cognitive test functioning (Alosco et al., 2013).

Those with mid-life obesity may run the risk of cognitive dysfunction/AD in later life. Cerebrovascular (CV) dysfunction showed a direct relationship with the duration of high-fat diet intake. The resulting hyperlipidemia disrupts CBF regulation and disrupts endothelial and smooth muscle function (Ayata et al., 2013). Obesity decreases CBF; it decreases the level of endothelium-derived nitric oxide (NO) (Toda et al., 2014). Obesity-enhances endothelial dysfunction while a decrease in CBF enhances A β production – the latter, in turn, impairs

endothelial function; this vicious pathological cycle promotes cognitive dysfunction (de la Torre et al., 2003; Toda et al., 2014).

In a recent interesting study on high-fat-diet-induced memory impairment in triple-transgenic Alzheimer's mice (3xTgAD), it was found that high-fat diet has rapid and sustained negative impact on memory (in control as well as in 3xTgAD mice) – this was ascribed to neuroinflammation in the AD mice. However, 3xTgAD mice at 3-4 months of age (compared to 15-16 months) have microglial activation, when fed with high-fat (Knight et al., 2014). The obese Zucker rat (OZR) represents a model of T2DM exhibiting increased arterial hypertension, vasoconstriction in the cerebral vasculature, and oxidative stress (Osmond et al., 2009). There is a significant increase in the astrocytic number in the OZR brain (in the frontal and parietal cortex, and in the hippocampus) (Tomassoni et al., 2013). Further, feeding saturated fat induces the hippocampal pathology and impaired cognitive function (Kanoski and Davidson, 2011). Higher BMI has been shown to induce the stroke at a significantly younger age (Dehlendorff et al., 2014).

2.5. Vitamin B12/Folate Deficiency

Vitamin B12/Folate intake has an impact on mental and physical health. A large number of elderly, even in the industrialized nations, consume less than recommended optimum amount of dietary nutrients. Up to 60%, elderly may be vitamin B12-deficient and about 29% folate-deficient. Poor cobalamin intake may cause atrophic gastritis resulting in lower gastric acid and pepsinogen secretion, and hence decreased absorption of B vitamins. B-vitamin deficiency may induce vascular disease (Hofmann et al., 2001; Huo et al., 2015; Kolb and Petrie, 2013; Shiran et al., 2015; Sudduth et al., 2013).

Homocysteine metabolism requires B vitamin cofactors. However, nutritional deficiencies in folic acid, vitamin B6 (pyridoxal phosphate), and B12 (methylcobalamin) enhance hyperhomocysteinemia (Hhcy). Vitamin B12/folate deficiency induces atherosclerotic lesions and neurocognitive decline. Folate deficiency is correlated with reduced cellular proliferation (17%) and increased apoptosis (16%) (Akchiche et al., 2012). In folic acid deficiency, homocysteine upregulates proatherogenic pathways including ROS and fibrin synthesis. However, folic acid (0.5-5 mg/d) supplementation significantly decreases homocysteine level (up to 25%) (Wolters et al., 2004).

In older adults, Hhcy increases CVD that may cause cognitive decline leading to AD. Older hypertensive individuals with Hhcy may undergo brain atrophy (Narayan et al., 2011) (see below). C57BL6/J mice were fed the vitamin B-deficient diet for ten weeks to induce Hhcy. This caused a significant pathology of hippocampal microvasculature and decreased spatial learning and memory (Throen et al., 2008). Chronic Hhcy increased pro-inflammatory TNF- α , IL-1 β and IL-6, chemokine CCL(2) and prostaglandin E(2) in the Wistar rats' hippocampus and serum (da Cunha et al., 2012). Hhcy may stimulate the vascular and cerebrovascular dysfunction in homocystinuria patients (da Cunha et al., 2012).

The frequency of the TT MTHFR genotype is quite high among individuals with B12 deficiency. This TT polymorphism in B12 deficiency correlated with endothelial dysfunction, and may be associated with potential vascular abnormalities that upregulate cardiovascular risk (Shiran et al., 2015). A model of VaD has been developed that induces Hhcy in mice. These mice develop neuroinflammation (determined by TNF- α , IL-1 β ,

and IL-6) and brain microhemorrhages. Increases in the matrix metalloproteinase 2 (MMP2) and MMP9 activity found in these animals are implicated in their cerebral hemorrhage pathology (Sudduth et al., 2013). Hhcy induced in mice by a methionine-rich diet increased atherosclerosis; it also enhanced RAGE (receptor for advanced glycation end products), VCAM-1, tissue factor, and MMP-9 in the vasculature (Hofmann et al., 2001). The above pathologies were significantly suppressed by feeding folate and vitamins B6/B12. Hhcy is a recognized factor that decreases gray matter thickness in bilateral frontal, parietal, occipital, and right temporal regions and lower gray matter volumes in left frontal, parietal, temporal, and occipital regions (Madsen et al., 2015). The above mentioned increases the risk for AD.

2.6. Diabetes

About 8% of the adult population suffers from T2DM. A direct association between glycemia and dementia has been shown in older persons (≥ 60 years old) with or without diabetes (Crane et al., 2013; Logue et al., 2011). Also, the correlation also exists between poor glucose metabolism (high fasting blood glucose) and lower executive function (Karlman et al., 2014), hippocampal atrophy, and lower memory, in older adults even without diabetes (Cherbuin et al., 2012; Kerti et al., 2013). Association also exists between insulin resistance and brain atrophy in those aged ≤ 60 years (Willette et al., 2013). It is known that cardiovascular risk factors, higher blood glucose, and memory decline are correlated in non-diabetic mid-life males (Anstey et al., 2015; Mortby et al., 2013). Further, in midlife adults, studies have reported: i) An elevated risk of vascular disease (Petrea et al., 2009), ii) Higher white matter pathology (Sachdev et al., 2004), iii) Enhanced glycaemia, and iv) Insulin resistance (Xu et al., 2013). After adjustment for hypertension, BMI, and smoking, only insulin sensitivity and C-reactive protein (CRP) were associated with a cognitive decrease in prediabetic stage (Anstey et al., 2015; Biessels et al., 2014).

Blood flow velocities (BFVs) were measured in the middle cerebral arteries of T2DM patients (and control). BFVs were negatively associated with HbA(1c) (A1C), and inflammatory markers. These data showed that reduced cerebral BFVs is related to increased resistance in middle cerebral arteries (Novak et al., 2006). Regional cerebral hypoperfusion and vasoreactivity, as well as cortical and subcortical atrophy, have been documented in the brain of T2DM patients. Patients with uncontrolled diabetes, therefore, may have enhanced hypoperfusion and brain atrophy. The resulting metabolic dysfunction in frontal and temporal regions from the effects mentioned above may impact negatively on cognition (Last et al., 2007). Indeed, cerebral perfusion is extensively compromised in the diabetic patients suffering from hypertension (Efimova et al., 2007; Last et al., 2007; ten Dam et al., 2007). CBF is significantly decreased in patients suffering from diabetic ketoacidosis (Yuen et al., 2008). T2DM is a vascular risk factor that may increase dementia risk. Neuronal cell death has been shown to increase in the hippocampus of the hypoperfused T2DM rats (Fukazawa et al., 2013; Kwon et al., 2015). This reflects that diabetes can enhance vascular-triggered cognitive dysfunction and promote dementia owing to cerebral hypoperfusion, inflammatory component, and neuronal degeneration (Kalaria et al., 2012; Rosenberg, 2009).

T2DM shares several risk factors with AD. While A β is deposited in AD brain, amyloid polypeptide APP called amylin accumulates within pancreatic beta-cells in T2DM. An increase in plasma glucose increases insulin levels even in subjects free of insulin resistance. This status has been shown to reduce 18F-FDG uptake in

precuneus/posterior cingulate, lateral parietal cortex, and frontal cortex – the AD-related regions (Ishibashi et al., 2015). Several studies have emphasized that T2DM may develop and persist in up to 30% of OSA patients (Kent et al., 2014; Pamidi and Tasali, 2012; Punjabi et al., 2004). Synergistically, they may modulate neuronal degeneration, and promote cognitive decline and AD (Daulatzai, 2013a; 2015b; 2015d). High stable glucose measures in younger individuals (25-59 YO; Compared to older persons) were associated with cognitive decline (after 12 years) (Anstey et al., 2015). A recent study evaluated the cognitive status of about 1000 diabetics and controls. The results showed that the occurrence of all-cause dementia, AD, and VaD was much higher in diabetics (4.8%, 2.7%, 1.4% respectively) compared to non-diabetics (2.2%, 1.2%, 0.4% respectively) (Zhao et al., 2012). The incidence of dementia and AD was significantly higher in T2DM patients carrying APOE ϵ 4 carriers (diabetics: 9.2%, non-diabetics: 3.3%) than APOE ϵ 4 non-carriers (diabetics: 6.3%, non-diabetics: 2.35%) (Zhao et al., 2012).

2.7. Depression

Significant research shows the relationships between depression, brain structural changes and cognitive decline, in older adults. 34 males (average age. 73.9) were studied with “multi-channel Near-infrared spectroscopy” (Uemura et al., 2014). rCBF was lower in the depressive subjects (compared with controls - the non-depressed) in the PFC. Further, there was less PFC activation in older depressed adults thus accounting for executive function decline (Uemura et al., 2014).

Single photon emission computed tomography (SPECT) was used to evaluate rCBF patterns in major depressive disorder (MDD) (Périco et al., 2005). An inverse relationship was present between severity of depressive mood and rCBF in the brain (notably amygdala, lentiform nucleus, and parahippocampal gyrus). A direct correlation with rCBF was, however, found in the right postero-lateral parietal cortex. Interestingly, specific rCBF patterns existed in variable MDD symptoms. For example, the severity of 1. Insomnia correlated inversely with rCBF in parts of anterior cingulate, insula and claustrum; 2. Anxiety correlated directly with rCBF in the right orbitofrontal cortex. Regions of orbitofrontal cortex and the left lentiform nucleus showed CBF that directly correlated with Cognitive performance (Périco et al., 2005; Bench et al., 1993). Another SPECT study on depression patients showed reduced rCBF in the PFC, left temporal lobe, and bilateral occipital lobes (Nagafusa et al., 2012). This work further showed that different specific symptoms may be associated with differing regional functional deficits in MDD, yet they are unaffected by age. As per a recent SPECT study, treatment-resistant depressed patients possess significantly low CBF in frontotemporal (bilateral), insular, anterior cingulate, and the caudate (left) regions (Richieri et al., 2015). rCBF was studied in MDD patients (compared with healthy controls) utilizing MRI with the arterial spin labeling method (which does not require radioisotopes) (Ota et al., 2014). Significant rCBF reductions were present in the prefrontal cortex (right inferior) and anterior cingulate in the MDD patients. The above results document a range of hypoperfusion and significant change in gray matter blood flow in major depression. The Pulsatility Index (PI) values and rCBFV parameters were also decreased in the cerebral arteries in depressive participants (Wang et al., 2014).

A meta-analysis of 23 studies identified conjoint decreases in rCBF and regional homogeneity in the insula and superior temporal gyrus in medication-free MDD patients. Also, altered rCBF was documented in the precuneus

and the frontal-limbic-thalamic-striatal neural circuit; the analysis showed altered regional homogeneity in the uncus and parahippocampal gyrus (Chen et al., 2015). A recent work has shown frontotemporal gray matter reduction in MDD patients and reduced rCBF in the anterior cingulate and parahippocampal region (bilateral). Interestingly, frontoparietal and striatal areas showed CBF increase (Vasic *et al.*, 2015).

2.8. Traumatic Brain Injury

Traumatic brain injury (TBI) is a major cause of disability and death. Initial management of TBI concentrates on prevention of subsequent secondary insults and cerebral hypoperfusion (Stein et al., 2011). TBI may cause memory impairment even after long-term following the insult (Stulemeijer et al., 2010; Dean and Sterr, 2013).

Indeed, a substantial single or repeated TBI may lead to a chronic traumatic encephalopathy and dementia (Walker and Tesco, 2013). Neuropathological findings after TBI may be similar to those found in AD. TBI may up-regulate axonal damage and A β 42 production, and down-regulate LTP (Walker and Tesco, 2013; Fakhra et al., 2013). Indeed, brain injury and ischemia could contribute to AD pathogenesis owing to cerebral circulatory and other abnormalities (Beckman et al., 2003).

There is evidence of significant pathology and altered metabolic milieu after TBI including edema, excitotoxicity, loss of neuronal and glial integrity, dysfunctional mitochondrial bioenergetics, oxidative stress, inflammation, and cell membrane disruption (Golding et al., 1999; Van Putten et al., 2005; Harris et al., 2012).

A substantial CBF reduction occurs in frontal and occipital cortices following sub-acute mild TBI (Lin et al., 2016). Consequently, a cascade of pathophysiological mechanisms is linked to vascular impairment-decreased CBF, brain hypoperfusion, glucose hypometabolism, and diminished energy supply (Olesen et al., 1981; Golding et al., 1999; Ayata et al., 2004; Parkin et al., 2005; Lauritzen et al., 2011; Romero et al., 2014).

TBI causes changes to brain's glucose uptake and its metabolism. Early after TBI, two deleterious features include: (1) regional cerebral oxygen tension and consumption decrease significantly in the cortex; and (2) at the same time point, glucose uptake is significantly reduced globally (Gajavelli et al., 2015; Jalloh et al., 2015). TBI affects brain glucose metabolism during sleep also and significantly lowers rCMRglc in the amygdala, hippocampus, parahippocampal gyrus, thalamus, insula, uncus, culmen, visual association cortices, and midline medial frontal cortices (Stocker et al., 2014). The dysfunctional cerebral glucose metabolism contributes to secondary brain damage (Clausen et al., 2011). However, systemic administration of beta-hydroxybutyrate (a ketone body) in TBI can effectively reduce ROS production in several cortical regions including the hippocampus and prevent neuronal death (Julio-Amilpas et al. 2015).

3. Framework Highlighting Pathological Ramifications and Cognitive Vulnerability Owing to Chronic Hypoperfusion and Glucose Hypometabolism

3.1 Diverse Comorbid Conditions Trigger Vascular Pathology

About 40% of AD patients may suffer from comorbid VaD. MRI, CBF and mean CThk were compared between patients with mild AD and MCI converters to AD (MCI-c) after two years of clinical follow-up (Lacalle-Aurioles et al., 2014). A significant hypoperfusion was noted in the parietal lobes of the MCI-c patients. This study indicated that rCBF deficits are already present in the MCI stage, emphasizing that CBF is a more sensitive parameter in MCI-c patients (Lacalle-Aurioles et al., 2014).

Cerebral hypoperfusion and metabolic dysfunctions are crucial features of AD that precede significant neuropathology. We need to unravel upstream factors/mechanisms that trigger the AD pathogenesis. *Prima facie*, vascular dysfunction causes reduced rCBF, and vascular pathology contributes to inflammation and oxidative stress causing vicious cycles. NADPH oxidase generates vasoactive superoxide in vascular pathology. The role of hypoperfusion and glucose metabolic dysfunction described in aging, diabetes, dyslipidemia, hypertension, and other comorbid risk conditions (delineated above) are potentially potent in upregulating vascular inflammatory and ROS-related pathological damage (Murray et al., 2011). Oxidative stress and activation of proinflammatory factors e.g. Hhcy are deemed causal in promoting atherosclerosis that in turn enhances hypoperfusion (Zhou and Austin, 2009).

There is a documented decrease in glucose metabolism with age in several brain areas. A recent FDG-PET study was done on 70-year-old normal individuals. There were statistically significant declines in FDG ratio in most cortical and subcortical regions, as a function of age (Knopman et al., 2014). 31.3% had elevated Pittsburgh compound B (PIB); however, no interaction was found between PIB status and Apolipoprotein E4 (APOE ϵ 4) genotype regarding glucose metabolism (Knopman et al., 2014). This study made other important observations. Carrying an APOE ϵ 4 allele was associated with reductions in FDG ratio in the posterior cingulate, precuneus, and lateral parietal regions. However, there was no interaction between “age and APOE ϵ 4 status”. They concluded that the above regions possess an inherently unique vulnerability to reductions in glucose metabolic rate in aging and carrying an APOE ϵ 4 allele (Knopman et al., 2014). There is another study of note, although on a single patient, with posterior cortical atrophy. Both amyloid and tau were studied with their specific tracers viz. PIB and [(18) F]AV-1451, respectively. While amyloid was found throughout association neocortex, “[(18) F]AV-1451 was selectively retained in clinically affected posterior brain regions that also showed a significant reduction in [(18) F]FDG uptake (Ossenkoppele et al., 2015).

A voxel-based analytical work showed significant hypometabolism but not atrophy in cognitively normal A β -positive subjects in comparison with cognitively normal A β -negative subjects (Kljajevic et al., 2014). This is in contrast to another recent study that found cognitively normal older adults with higher amyloid deposition are relatively hypermetabolic in some brain areas, e.g. frontal and parietal (Oh et al., 2014). A 9-year longitudinal study was conducted on MCI patients employing serial brain imaging with PIB (Knopman et al., 2015). It was found that the patients positive for amyloid and neurodegenerative changes showed volumetric and metabolic worsening in their temporal and parietal association areas (Knopman et al., 2015). Thus, clearly more extensive work is needed to evaluate both amyloid deposition and NFT concurrently - since many studies do not carry out the simultaneous evaluation of tau status in A β -positive or negative subjects.

Current evidence shows age-related cerebral microvascular pathologies. These include tortuous blood vessels/capillaries, venous collagenosis, low vascular density, and microembolic brain injury that lead to compromised blood supply. A decrease in cerebrovascular angiogenesis may impact recovery from ongoing OSA/hypoxia-related factors. Most lipid microemboli from the heart may remain for weeks in the brain (Brown and Thore, 2011). Consequently, there is a functional failure of the aging microvasculature; this is also noted in AD brain emphasizing the possible role of the compromised brain microcirculation and decreased cerebral metabolism in AD pathogenesis (Farkas and Luiten, 2001; Hunter et al., 2012). These factors may impact drainage of A β along perivascular elimination pathways in aging artery walls (Weller *et al.*, 2009) (see below).

Recent work has shown that Hhcy is an important independent risk factor that induces arterial pathology. Also, endothelial injury and inhibition of insulin sensitivity are promoted by Hhcy (Liu et al., 2014). The arterial endothelial dysfunction occurs in OSA, hypertension, Hhcy, and insulin resistance (Liu et al., 2014). A significant number of elderly suffer from the above-combined stigmata that may induce arterial stiffness and a decrease in rCBF; the ensuing hypoperfusion would increase cerebrovascular damage (Chung et al., 2010). Mice fed a diet depleted of folate and vitamins B6 and B12 showed an increase in atherosclerotic lesion. The vasculature of these mice showed an enhanced expression of the receptor for advanced glycation end products (RAGE), VCAM-1, tissue factor, and the MMP9. However, the above effects decreased significantly following reintroduction of folate and vitamins B6 and B12 in the diet (Hofmann et al., 2001). Similarly, vascular dyshomeostasis and endothelial dysfunction occur in obese individuals with prehypertension, prediabetes, hyperinsulinemia, and insulin resistance (Gupta et al., 2012). Hence, chronic cerebral hypoperfusion would lead to neural injury and cognitive impairment (see below).

VaD patients are known to develop several vascular lesions (confirmed by MRI and histology) including microhemorrhages, hemorrhagic infarcts, or ischemic infarcts. Mice subjected to hyperhomocysteinemia develop neuroinflammation reflected by elevated TNF- α , IL-1 β , and IL-6, (Sudduth et al., 2013). An earlier study on diet-induced Hhcy in mice (Hofmann et al., 2001) found higher levels of the MMP2 and MMP9. The latter is implicated in the development of cerebral hemorrhage. Hhcy induced spatial memory deficit (radial-arm water maze test) in the mice. There are growing data that low Vitamin B12 is directly associated with AD. A combination of high Hcy and low vitamin B12/folate levels are found in AD (Chen et al., 2015). A recent meta-analysis also corroborated that the above factors may increase AD risk (Shen and Ji, 2015). Vascular risk factors underlie AD or vaD (Fig. 1.). Ethanol abuse and hypercholesterolemia also underlie pathologies that are similar to AD (Ullrich et al., 2010). Long-term ethanol treatment in adult Sprague-Dawley rats spatial memory dysfunction; this was owing to decreased cortical acetylcholine, elevated cortical monocyte chemoattractant protein-1 and tissue-type plasminogen activator, microglia increase, reduced number of choline acetyltransferase- and p75 neurotrophin receptor-positive neurons in the nucleus basalis of Meynert. Further, the ethanol-treated rats displayed BBB leakage. Thus, ethanol and cholesterol may be causative in cognitive dysfunction in AD and vaD (Ehrlich et al., 2012).

3.2 Cerebral Amyloid Angiopathy (CAA)

The CAA increases with age; almost 100% elderly 80 years and over have CAA. In CAA, A β peptide is deposited within the walls of the blood vessels and capillaries. CAA and hypoperfusion enhance deposition of leptomeningeal A β . CAA may originate from neurons. According to drainage hypothesis, neuronally-produced A β crosses the blood-brain barrier (BBB) (Burgermeister et al., 2000). Another theory suggests that A β originates in the circulating bloodstream. A β may also be generated by vascular smooth muscle cells, and pericytes (Revesz et al., 2002). Regardless of its origins, A β is deposited and builds up on the walls of the blood vessel due to its increased accumulation and decreased clearance (deficiency in the A β transport) (Segare et al., 2013). This would cause narrowing of the lumen and induce vascular pathology. CAA induces the degeneration and death of endothelial cells (Ferrer et al., 2004).

ROS-mediated vascular/endothelial and BBB dysfunction (Ferrer and Keller, 2012 and Freeman et al., 2012) due to A β may induce inflammatory responses causing migration of leukocytes across blood vessels (Sutton et al., 1999; Thomas et al., 1997). Further, A β mediates production of TNF- α and IL-1 β that in turn mediate inflammatory response and vascular pathology (Sutton et al., 1999). Hence, while CAA increases cerebral hypoperfusion, conversely hypoperfusion accelerates CAA (Okamoto et al., 2012). Besides, A β may disrupt Blood-CSF barrier integrity (Brkic et al., 2015).

The rat brain capillary endothelial cells (RBE4), deprived of oxygen and glucose generated 250% increase in A β 42 production. The mechanism has been shown to be time-dependent and involves the HIF1-mediated β -secretase (BACE1) and APP gene up-regulation. This work clearly showed that oxygen and glucose deprivation has a direct impact on endothelial cells of the brain to upregulate the intra-endothelial cell deposition of A β 42 (Bulbarelli et al., 2012).

In AD, CAA has been shown to range from 70% to 97.6% (Attems, 2005). CAA may cause microscopic bleeding in the neocortex making it an important AD pathology (Jellinger, 2007). This has been corroborated recently (De Reuck et al., 2013; Samuraki et al., 2015). CAA-related microbleeds were located (in 158 AD patients) mainly in cortex and subcortex, but in the occipital lobe also. Patients with CAA-related microbleeds showed glucose hypometabolism and gray matter atrophy in the temporal lobe and cerebellum. Consequently, it was concluded that CAA-related microbleeds are causative regarding gray matter atrophy and glucose hypometabolism in AD (Samuraki et al., 2015). Sustained cerebral hypoperfusion through microinfarcts, hemorrhage, and white matter disruption produced glio-vascular alterations and cognitive deficits (Holland et al., 2015).

In Tg2576 mice, human apoE4 expression caused substantial CAA at 15 months of age (Fryer et al., 2005). When microvessels are pathological, they may contribute to neuronal injury and death by releasing toxic factors that directly injure neurons (Grammas, 2000). Microvessels isolated from AD brain release higher levels of monocyte chemoattractant protein (MCP-1), TNF- α , IL-1 β , and IL-6, compared to microvessels from non-AD brain (Grammas and Ovas, 2001). The AD microvessels secrete a high level of neurotoxic inflammatory mediators including protease thrombin and the inflammation-associated proteins IL-8, α V β 3, and α V β 5 integrins (Grammas et al., 2006). These neurotoxic agents upregulate the “pathologic activation of cerebral microvasculature” and dysfunctional endothelial cells may lead to neuronal injury/loss in AD brain (Grammas et al., 2002).

The transgenic A/T mice (APP(Swe, Ind)) overexpress a mutated form of the APP and transforming growth factor- β 1 (TGF- β 1). In these aged mice, chronic inflammation triggers a cascade leading to several AD-like pathophysiological features - encompassing cerebrovascular amyloidosis, microvascular fibrosis and degeneration, hypoperfusion, and cerebrovascular amyloid angiopathy. These lead to significant alterations in metabolic activity in different brain regions implicated in learning and memory processes (Wyss-Coray et al., 2000; Buckwalter et al., 2002). Further, these mice displayed deficient neurovascular and neurometabolic coupling to whisker stimulation, and memory performance (Ongali et al., 2010). At nine months of age, these mice had degenerative alterations in endothelial cells and pericytes, associated with decreased regional cerebral glucose utilization (Wyss-Coray et al., 2000; Hamel, 2015). Further, they showed a decline in NO activity in

vessel walls and cerebrovascular function with dilatory deficits thus causing decreased vessel tone (Papadopoulos et al., 2014; Tong and Hamel, 2015). Hence, endothelium-mediated vascular dysfunction may be an important component in AD pathogenesis (Di Marco et al., 2015).

3.3 Blood–Brain Barrier (BBB) Dysfunction

The neurovascular unit is comprised of brain microvascular endothelial cells and astrocytes that regulate BBB permeability. This interface *viz.* the BBB protects the brain from any noxious molecules in peripheral circulation. BBB is an important component of the vascular hypothesis (Rocchi et al., 2009; Valenti et al., 2014; Canobbio et al., 2015; Janota et al., 2015; Rius-Pérez et al., 2015; Di Marco et al., 2015). Indeed, hypoperfusion, hypoxia and neuroinflammation due to various factors may lead to BBB leakiness and apoptosis in AD (Biron et al., 2011; Hartz et al., 2012; Heye et al., 2014; Yang et al., 2015; Michael et al., 2015; Banks et al., 2015; Nathoo et al., 2016). In mild-to-moderate AD, the BBB undergoes significant disruption during the disease progression (Bowman et al., 2007). In AD progression, the BBB permeability is crucial in letting the neurotoxic substances such as pro-inflammatory cytokines enter the CNS (Bell et al., 2009; Desai et al., 2002; Lashuel, 2005; Persidsky et al., 2006; Simionescu and Antohe, 2006).

Aging reduces BBB integrity, and this is linked to AD (Altman and Rutledge, 2010; Deane and Zlokovic, 2007). Also, a high-saturated-fat and cholesterol (HFHC) diet contributes to BBB breakdown. Activated microglial cells play a significant role in altering the BBB integrity (Hawkins and Davis, 2005). Increase in microglial activation was shown in aged rats receiving the HFHC diet (Freeman and Granholm 2012). The lipopolysaccharide-stimulated inflammation enhances BBB disruption, activated microglial cells, and damaged endothelial cells causing their death (Kacimi et al., 2011). Rats with hypoperfusion (after transient middle cerebral artery occlusion) underwent both microglial activation and neuronal loss (Emmrich et al., 2015).

Chronic sleep restriction (CSR) may also induce BBB dysregulation. The latter may occur via inhibition of endothelial and inducible nitric oxide synthase (eNOS and iNOS, respectively), endothelin1 upregulation, and decreased 2-deoxy-glucose uptake. As little as six days of CSR was enough to impair BBB dysfunction - decreasing several tight junction proteins, and increasing BBB permeability. Interestingly, following just 24 h of recovery sleep, the BBB permeability became normal (He et al., 2014).

3.3.1 Disruption of Glucose Uptake Impairs BBB Integrity

There is hypometabolism of differing severity in different regions of the AD brain. Cerebral hypometabolism reflected by a reduction in glucose utilization begins decades before any AD symptoms or histopathologic changes. The increase in plasma glucose levels reduces 18F-FDG uptake in precuneus/posterior cingulate, lateral parietal cortex, and frontal cortex in AD-related regions. The potency of this phenomenon is such that it can occur even in normal individuals without insulin resistance (Ishibashi et al., 2015).

90% of brain energy is supplied by glucose metabolism (Handa et al., 2000). The blood glucose concentration and transporter protein are the rate-limiting factors for its transport into the brain. Any disruption of BBB integrity interferes with glucose uptake. Chronic ethanol abuse impairs glucose tolerance and causes inability to maintain plasma insulin levels (Wilkes and Nagy, 1996). Recent work measured the glucose metabolism in different brain regions of the chronic alcoholics by FDG-PET (Volkow et al., 2006), and found a decline in

glucose metabolism in the frontal cortex. Additionally, alcohol consumption enhances monocytes migrating across the BBB, and ROS-mediated BBB disruption (Haorah et al. 2005b; 2007a; 2007b). Several other mechanisms are implicated in the alcohol-induced BBB disruption; these include activation of myosin light chain kinase (Haorah et al. 2005a), inositol 1,4,5-triphosphate-gated intracellular Ca^{2+} release (Haorah et al. 2007a; 2007b), and protein tyrosine kinase-mediated matrix metalloproteinase signaling pathways (Haorah et al., 2008a; 2008b).

3.3.2 BBB Disruption Promotes Neuronal Loss

In cultures of neuron and astrocyte (human stem cell-derived), treatment with $\text{A}\beta_{42}$ induces hypometabolism.

The $\text{A}\beta$ -exposed cultures displayed decreases in glucose uptake and its utilization (Tarczyluk et al., 2015). The latter has been shown to disrupt the energy-redox axis reflected by changes in $\text{NAD}^{+}/\text{NADH}$, ATP, and glutathione levels (Tarczyluk et al., 2015). The pyruvate uptake, (an important energy source in the brain mitochondria) was lower after $\text{A}\beta_{42}$ treatment of the cultures; this, however, decreased ATP but increased Ca^{2+} and ROS levels. Consequently, unlike astrocytes, the neurons succumbed to death (Tarczyluk et al., 2015).

Alcohol negatively interferes glucose metabolism in the brain (Handa et al. 2000; Volkow et al. 2006). The BBB dysfunction would adversely affect the uptake and utilization of glucose by neurons and glial cells. This would impact their survival as well. Indeed, this has been confirmed in that attenuation of glucose uptake causes neuronal degeneration (Abdul Muneer et al., 2011a; 2011b). Alcohol significantly inhibited the uptake and transport of glucose across the BBB; this was validated by both *in vitro* and *in vivo* findings.

Decreases in glucose transport across the BBB (e.g. due to alcohol) and glucose uptake in cells correlated with reduction of GLUT1 protein (due to defective mRNA biosynthesis of GLUT1) expression in cell culture and brain microvessels (Abdul Muneer et al., 2011a). The above mentioned causes further breakdown of BBB integrity (Abdul Muneer et al., 2011a). Consequently, cerebral glucose hypometabolism may lead to neurotoxicity and neuronal degeneration (Fig. 1.).

3.3.3 Hypoperfusion and Neuronal Death

The mechanisms underlying neuronal death due to chronic cerebral hypoperfusion has been extensively studied (Martin et al., 2000). Ultrastructurally and immunocytochemically, degenerating hippocampal CA1 pyramidal neurons and cerebellar Purkinje cells undergo necrosis, while degenerating granule neurons show both necrotic and apoptotic processes. Indeed, the vulnerable neurons undergoing degeneration after hypoperfusion/ischemia are mediated by the apoptosis-necrosis continuum (MacManus et al., 1995; Martin et al., 2000; and Portera-Cailliau et al., 1997a; 1997b). Neurodegeneration due to hypoperfusion involves intracellular Ca^{2+} dyshomeostasis and excitotoxic activation of neuronal glutamate receptors (GluRs) (Diemer et al., 1993).

Several other deleterious changes occur in neurons after hypoperfusion; these may include damage to the plasma membrane and cytoplasmic organelles. In neuronal degeneration (Laiho et al., 1971; Laiho and Trump, 1975; Martin et al., 2000) mitochondrial dysfunction causes a decrease in ATP synthesis (Laiho and Trump, 1975). Indeed, as early as 6 hours after cerebral ischemia, total protein synthesis is severely reduced particularly in vulnerable neurons (Araki et al., 1990; Furuta et al., 1993; Johansen and Diemer, 1990; Thilmann et al., 1986) followed by a lack of restoration of biosynthetic function. Early after hypoperfusion, cytoskeletal disintegration

occurs in dendrites, before degeneration of neuronal cell bodies (Kitagawa et al., 1989; Yamamoto et al., 1990). The above pathophysiological abnormalities persist during the process of neurodegeneration (Kirino, 1982; Kirino and Sano, 1984; Kirino et al., 1984; Martin et al., 1998). Of note, CNS ischemia has a deleterious impact on non-neuronal cells also - astrocytes, oligodendrocytes, inflammatory cells, and vascular cells die apoptotically (Martin et al., 1997a; 1997b; 1998). Signaling pathway mediated by the HIF is an important compensatory protective mechanism; it is triggered by pathophysiological conditions including hypoxia and ischemia. Hypoxia-inducible factor 1- α (HIF-1 α) activation was studied in the animal model of chronic cerebral hypoperfusion. HIF-1 α increased as early as 12 h after hypoperfusion and continued increasing for 56 days. Importantly, there is the sustained increase of HIF-1 α during chronic cerebral hypoperfusion - but without any protective effect (Yang et al., 2013).

3.4 Cerebral Hypometabolism

There is evidence that AD patients suffer from abnormal forward glucose transport in the cortical brain regions (Jagust et al., 1991; Piert et al., 1996). The impaired glucose metabolism is said to be the basis for neuronal/synaptic dysfunction and cognitive decline. The functional biomarker CMRglc in conjunction with changes in the brain volumes is valuable to gain information about disease progression and drug treatment outcome. A CMRglc study in the aging-associated cognitive decline identifies patients with metabolic alterations, and who may develop aMCI (Hunt et al., 2007); it may also predict those aMCI patients who may subsequently convert to AD (Herholz et al., 2007). MCI converters to AD possess a much lower CMRglc in the right cingulate, left inferior parietal and left temporal gyrus, and most of their brain areas undergo significantly decreased CMRglc during AD progression (Ishii et al., 2009).

12 weeks of hypoperfusion decreases CBF by 26% in CAA mice (compared to wild-type mice), indicates perivascular A β accumulation and impaired microvascular function. This study also documented that cortical microinfarcts in AD brains are mainly located close to CAA afflicted vessels (Okamoto et al., 2012).

FDG-PET studies have highlighted CMRglc abnormalities in preclinical individuals in their 40's (Reiman et al., 2004). CMRglc reductions in the Hippocampus during normal aging is considered to predict cognitive decline much earlier than the clinical diagnosis (Mosconi et al., 2008). The dysfunctional entorhinal cortex (EC) connection has been implicated in cortical hypometabolism. Assessment with FDG-PET pointed out CMRglc reductions in the EC and the ipsilateral temporooccipital cortex (Mosconi et al., 2004). Importantly, Presymptomatic familial early-onset AD individuals have an absence of brain atrophy but show significant widespread MRglc reductions (Mosconi et al., 2006). Reduced CMRglc was found only in posterior cingulate cortex (PCC) in aMCI patients; however, low CMRglc was present in AD in several areas including frontal, parietal, temporal, and occipital cortex (O'Brian et al., 1992). Other studies on AD have also documented CMRglc reductions in the PCC, precuneus, temporoparietal and frontal multimodal association regions (Del Sole et al., 2008; Herholz et al., 2007). Worth noting is the fact that aging-associated cognitive decline patients (who later converted to AD) showed the metabolic decline in more extensive regions, viz. frontal and temporal cortices, right cingulate gyrus, right thalamus, and bilateral precuneus (Hunt et al., 2007). However, in

subcortical vascular dementia patients, the glucose hypometabolism was more severe in the thalamus, brainstem, and cerebellum (Seo et al., 2009).

When AD patients were studied with FDG-PET after one year (from the baseline), they had a significant decline in glucose metabolism in frontal, parietal, temporal, and posterior cingulate cortices (Alexander et al. 2002). In another study, 16 AD patients were followed up for two years, and interval change in amyloid deposition and CMRglc studied. Relative PIB retention in cortical regions differed by 3-7%; in contrast, CMRglc decreased by 20%. Interestingly, this follow-up study showed a significant negative correlation between CMRglc and PIB retention in the parietal cortex. (Engler et al., 2006). An interesting study in AD patients has documented that hypometabolism in parietal and precuneus regions is negatively correlated with PIB retention in AD patients (Cohen et al., 2009). However, others have found a positive correlation between PIB and CMRglc in all cortical regions studied but particularly in the posterior cingulate and parietal cortices (Forsberg et al., 2012). The reasons for the above discrepancy is not known. Finally, an elegant study in baboons has highlighted the interrelationship between rhinal cortex pathology and the CMRglc decline in the inferior parietal, posterior temporal, posterior cingulate, and the posterior hippocampal regions (Meguro et al., 1999). Importantly, as much as 49.9% decrease of CMRglc may occur in the parietal cortex of the AD patients (Piert et al., 1996).

Neuronal damage and dysfunction in the rhinal cortices may cause glucose hypometabolism in several brain areas; this is said to play a significant role in the pathogenesis of AD (Meguro et al., 1999; Millien et al., 2004; Daulatzai, 2015b). FDG PET studies suggest that normal anatomico-physiological connections with the EC are important to maintain cortical glucose metabolism. Conversely, decreases in the CMRglc in the temporoparietal and hippocampal areas noted in AD may be due to their disconnection with the rhinal cortex (Meguro et al., 1999; Millien et al., 2004; Mosconi et al., 2004; Daulatzai, 2013a; 2013b; 2014; 2015b; 2015c).

3.5 Brain Atrophy: A Defining Impairment in Multiple Risk Factors

3.5.1 Aging

Aging is associated with cognitive decline in some (but not all) aged persons. Owing to susceptibility, the vulnerable persons begin to decline from their 40s onwards. Significant pathology may continue to accumulate at the time they are in their 50s and 60s. Age-related cognitive decline correlates with decreases - in regional brain volume (Allen et al., 2005; Fotenos et al., 2005; Sowell et al., 2003), cortical thickness (Magnotta et al., 1999; Salat et al., 2004), and white matter (Pfefferbaum et al., 2006; Salat et al., 2005). There is an ongoing accumulation of NFT (Del Tredici and Braak, 2008) and A β (Beckmann et al., 2003; Bennett et al., 2005; Okamoto et al., 2012; Okonkwo et al., 2014).

Healthy aging is associated with widespread age-related neuroanatomical volume change. The brain volume loss of 0.2% per year occurs after age 35 years. This is followed by a decrease in brain volume loss of 0.5% annually at age 60. However, in over 60 years old, the volume loss is more than 0.5% in the brain (Hedman et al., 2012). With older age, gray matter (GM) volume was lower in the sensorimotor, frontal, temporal, occipital, and parietal lobes, as well as in the cerebellum, posterior hippocampus, thalamus, and middle cingulate gyrus (Raji et al., 2009; Walhovd et al., 2011). In the presymptomatic stage with no cognitive decline, hypertension and AD are additive in enhancing gray matter damage (Glodzik et al., 2012). Interestingly, in *Aplysia californica*, the

neurons express genes related to apoptosis and AD; however, these are expressed differentially in older animals. This was inter-related to (i) changes in histones, (ii) DNA methylation, and (iii) regional relocation of RNAs; these alterations are thought to underlie age-related changes in neuronal functions and synaptic plasticity (Moroz and Kohn, 2010). Importantly, normal aging has little effect on medial temporal lobe volume loss (Dickerson et al., 2009; Salat et al., 2004).

3.5.2 Obesity

Obesity is a risk factor for AD (Kivipelto et al., 2005). Higher cortisol secretion may decrease brain volume (Bjorntorp, 2001; Simmons et al., 2000). Several studies have emphasized the brain volume decline as a function of obesity (Gustafson et al., 2004; Pannacciulli et al., 2006; Ward et al., 2005). In one study over a 6-year period, BMI was shown to influence gray matter volume (Taki et al., 2011). OSA is one of the risk factors for obesity. Data show that OSA patients undergo a reduction in their gray matter (compared with non-apnoeic controls) (Morrell et al., 2010). Indeed, gray matter volume decreases have been confirmed in the left hippocampus, EC, left PCC, and right superior frontal gyrus (Canessa et al., 2011). After CPAP treatment, memory, attention, and executive functioning were significantly improved; concomitantly gray matter volume increased in the hippocampus and frontal cortex (Canessa et al., 2011). Using tensor-based morphometry (TBM) and computational analysis, the study showed that increase in body's adipose tissue (hence greater BMI) correlates with lower brain volumes in the hippocampus, orbital frontal cortex, and parietal lobes in cognitively normal elderly adults (Raji et al., 2010). Recent proton magnetic resonance spectroscopy (MRS) studies also showed that higher BMI lowers neuronal viability in the brain regions including, frontal, parietal, and temporal lobes (Gazdzinski et al., 2009). In effect, every unit increase in BMI was associated with a 0.5%–1.5% average brain tissue reduction in MCI and AD patients studied (after controlling for age, sex, and education) (Ho et al., 2010; Verstynen et al., 2012). The BMI associated brain atrophy is predominantly in the white matter (Gregoire et al., 2011; Verstynen et al., 2012).

3.5.3 Homocysteine

Homocysteine is an agonist at N-methyl-D-aspartate (NMDA) receptor (the glutamate binding site), but as a partial antagonist at the glycine receptor site. It mediates excitation at the Schaffer collateral-CA1 synapses (at NMDA receptors) in the hippocampus (Ito et al., 1991). Under physiological conditions, modest Hhcy may contribute neurotoxicity via overstimulation of NMDA receptors (Lipton et al., 1997; Schwarz et al., 1990). Excessive stimulation of these receptors mediates brain damage (Lipton and Rosenberg, 1994; Simon et al., 1984).

Elevated homocysteine enhances brain atrophy rates in older hypertensives (Narayan et al., 2011). Hhcy correlates with white matter atrophy and hippocampal atrophy (Firbank et al., 2010; Choe et al., 2014). Recent multiple linear regression analyses have confirmed that plasma total homocysteine level has a significant impact on hippocampal volume (after controlling for the amyloid beta deposition, vascular burden, age, gender, education, and ApoE4 genotype). Indeed, homocysteine has a direct adverse impact on the hippocampus, not mediated by A β (Choe et al., 2014). However, B-vitamin treatment decreases (7 fold) the gray matter atrophy in the medial temporal lobe (Douaud et al., 2013).

Under pathological conditions, the neuronal damage is a function of excessive Ca^{2+} influx and higher ROS. ROS can be generated extracellularly by homocysteine (Stamler et al., 1993) causing excessive NMDA receptor stimulation, cytochrome c release, neurotoxicity, and apoptosis (Baydas et al., 2005; Ho et al., 2001; Lafon-Cazal et al., 1993; Lipton et al., 1997). Importantly, superoxide dismutase and catalase may offer protection from neuronal damage (Truelove et al., 1994). Overstimulation of NMDA receptors leads to increased level of cytoplasmic Ca^{2+} by L-glutamate, and mitochondrial pathology (Kim et al., 1999; Wang et al., 1999). 14-3-3 brain protein suppresses apoptosis mainly through sequestration of Bad, a pro-apoptotic protein (Brunelle et al., 2009; Dougherty et al., 2004; Yacoubian et al., 2010). However, the level of 14-3-3 ϵ is significantly reduced after reducing homocysteine (Wang et al., 2012).

3.5.4 Sleep Deprivation

Chronic sleep deprivation (CSD) may compromise neuronal stability and induce cell death (Daulatzai, 2013a; 2015b; 2015d). A recent study has shown significantly reduced hippocampal volume in sleep-restricted animals (Novati et al., 2011). The hippocampus of young and aged animals subjected to CSD showed apoptosis and cell death (de Souza et al., 2012). This was ascribed to Ca^{2+} signaling dysregulation (de Souza et al., 2012). CSD produces unhealthy physiological consequences. Indeed, healthy adults subjected to CSD manifest adverse effects on endocrine, metabolic and inflammatory functions. Furthermore, the CSD-induced increase in brain $\text{TNF-}\alpha$ and $\text{IL-1}\beta$ and decrease in hippocampal BDNF might contribute to neurocognitive decline (Zielinski et al., 2014). Finally, synapses are affected by sleep. Excitatory synapses change their efficacy; they grow or shrink – as a function of sleep. Sleep deprivation affects the synaptic function of LTP (long-term potentiation) (Cirelli, 2013). Consequently, sleep restriction has a potent impact on neurobehavioral, memory, and cognitive functions.

3.5.5 Chronic Alcohol Abuse

Chronic alcohol abuse is one of the common reasons for neurodegeneration. Excessive consumption of alcohol is associated with neurodegeneration and cognitive dysfunction, as well as microglial activation (Zhao et al., 2013). Cerebral microbleeds occur in heavy drinking (Ding et al., 2015). The loss of dopaminergic and cholinergic neurons from chronic alcohol administration occurs in the hippocampus and striatum. Copious data also document that alcohol-induced neurodegeneration (AND) is related to enhanced oxidative stress, increased NF-kappaB transcription, and proinflammatory proteins – both are neurotoxic (Crews and Nixon, 2009). Ethanol disrupts synaptic signaling in the hippocampus causing spatial memory decline (Wright et al., 2003). However, blocking of oxidative stress and NF-kappaB transcription, and increasing CREB transcription may nullify the above derangements (Crews and Nixon, 2009).

3.6 Elderly and Cognitive Impairment

Cognitively healthy elderly having pathological biomarkers for AD may not progress to AD (Lue et al., 1999; Riudavets et al., 2007; Iacono et al., 2008; Erten-Lyons et al., 2009; Kramer et al., 2011; Bjorklund et al., 2012). Conversely, a significant proportion of elderly having cognitive and memory concerns/impairment do not necessarily convert to dementia/AD either (Marchant et al., 2013; Wirth et al., 2013; Hwamee et al., 2014; Mormino et al., 2014; Amariglio et al., 2015).

Longitudinal, observational study with serial brain imaging (conducted over 10 years) in a population-based cohort has shown that older subjects even positive for neurodegeneration can lack an AD metabolic profile and pathophysiology (Knopman et al., 2015). Indeed, older adults may possess age-related gray matter atrophy across the whole brain, regardless of A β deposition (Oh et al., 2014; Jansen et al., 2015; Foley et al., 2015). Importantly, the presence of brain amyloidosis alone is not sufficient to produce cognitive decline (Jack et al., 2008; 2009; 2015). A discussion on A β deposition and neuroimaging (PIB), and other biomarkers, in cognitively normal elderly and those with preclinical AD, is beyond the scope of this paper.

Subtle losses in cognitive function may not always be symptomatic of AD. However, among “vulnerable” elderly, about 79.5% in age group 90 years (or older) and 46.7% among those aged 71–79 transition to AD (Brookmeyer et al., 2011). The overall prevalence of MCI (in the United States) for individuals aged 71 years or older is reported to be 22% (Brookmeyer et al., 2011). Of these, the annual conversion rate in 3 years (in clinical samples) from MCI to AD is about 8–15% (Devanand et al., 2008). Estimations have shown that AD accounts for approximately 69.9% of all dementia while VaD being 17.4%. Other types of dementia including Parkinson's dementia, normal pressure hydrocephalus dementia, frontal lobe dementia, alcoholic dementia, traumatic brain injury-related dementia, and Lewy body dementia (to name a few) account for about 12.7% cases (Brookmeyer et al., 2011).

4. Cerebral Hypoperfusion: Therapeutic Approach

Several therapeutic substances have been documented that attenuate cerebral hypoperfusion. Some of the selected ones are mentioned below. The therapeutic approach is subdivided as follows into 1. Reperfusion-Rehabilitation Approach, 2. Pharmacological Approach, and 3. Nutraceutical Approach.

4.1 Reperfusion-Rehabilitation Approach

The brain reperfusion-rehabilitation therapeutic strategy has been presented recently. The effect of the brain reperfusion rehabilitation therapy (BRRT) was evaluated in 15 patients with mild AD. They underwent BRRT for 12 months with significant improvement in tissue oxygen saturation (measured with near-infrared spectroscopy), Mini-Mental State Examination (MMSE), and Rey Auditory Verbal Learning (RAVLT) tests. This indicates that the attenuation of hypoperfusion may result in improvement in verbal memory-learning and global cognitive impairment (Viola et al., 2014).

4.2 Pharmacological Approach

Minocycline

Minocycline is a tetracycline derivative that reduces inflammation and ameliorates cerebral ischemia. It controls oxidative stress and attenuates the cognitive decline in an animal model of chronic cerebral hypoperfusion (Wistar rats) (Cai et al., 2008). A decrease in the relaxant NO enhances cerebral ischemia, and minocycline down-regulates expression of iNOS but upregulates eNOS. Its beneficial effects include decreasing oxidative stress and apoptosis and protecting neural function (Cai et al., 2008).

Cilostazol

Chronic cerebral hypoperfusion was induced in T2DM rats. These rats were treated with cilostazol - a potent inhibitor of type III phosphodiesterase. Cilostazol was significantly beneficial in these hypoperfused animals; it

inhibited neuronal cell death, activated CREB phosphorylation, upregulated BDNF expression, and improved memory impairment (Kwon et al., 2015). Cilostazol also improved endothelial dysfunctions in mesenteric arteries of T2DM rats. This endothelial effect of cilostazol treatment is via improved: (a) acetylcholine-induced relaxation and (b) cyclic adenosine monophosphate (cAMP)-mediated relaxations (Matsumoto et al., 2008; Miyamoto et al., 2009). An earlier study also showed protective effects of cilostazol on focal cerebral ischemia - through decreasing TNF- α level, Bax protein level, cytochrome c release, and increasing the levels of Bcl-2 protein (Choi et al., 2002). This led to a decrease in brain ischemia, and oxidative apoptotic cell death (Choi et al., 2002). A recent study corroborated some of the above data and further documented that cilostazol upregulated p-CREB and Bcl-2, as well as increased cyclooxygenase-2 expression, and reduced microglial activation. Thus, cilostazol is brain-protective and may be potentially useful in ameliorating cognitive impairment (Watanabe et al., 2006). Several elements of the above studies have been confirmed in the rats subjected to focal transient ischemic damage (Hong et al., 2006) and chronic cerebral hypoperfusion (Lee et al., 2008).

Edaravone

Edaravone is another important therapeutic candidate for consideration in treating cerebral hypoperfusion. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a potent free radical scavenger; its antioxidant function inhibits lipid peroxidation. It is used clinically for the treatment of acute cerebral ischemia. In a rat model of chronic hypoperfusion, edaravone protected axonal damage, and provided protection against white matter lesions; the mechanisms for these included endothelial protection and free radical scavenging (Ueno et al., 2009). In a rat model of transient global cerebral ischemia, the beneficial effect of edaravone in the hippocampus included: increased number of neural stem/progenitor cells and newly generated neurons in the subgranular zone, decreased apoptosis of neural stem/progenitor cells, decreased ROS generation, and inhibition of HIF-1 α and caspase-3 expression (Lei et al., 2014). Edaravone's benefit in hypoxic-ischemic injuries in the brain (Noor et al., 2005; Sun et al., 2015; Zhang et al., 2012) and other tissues (Doi et al., 2004; Taniguchi et al., 2007) is well documented.

Gallic acid

ROS-mediated damage is implicated in cerebral hypoperfusion. Gallic acid (GA) is another antioxidant therapeutic that exerts the benefit through attenuating free radical-induced neural damage in cerebral hypoperfusion. In an animal model (rat) of vascular dementia, hypoperfusion reduced total thiol and glutathione peroxidase (GPx) antioxidants but increased malondialdehyde (MDA) level - in both hippocampus and frontal cortex. There was a concomitant decrease in spatial memory. However, when GA was administered (chronically), it increased total thiol and GPx contents and decreased MDA levels. GA administration significantly enhanced the spatial memory (Korani et al., 2014; Mansouri et al., 2013).

S-nitrosoglutathione

S-nitrosoglutathione (GSNO) is the nitric oxide carrier; it decreases A β accumulation in the brain and improves cognitive function. In chronically hypoperfused rat brains, GSNO treatment decreased iNOS expression and nitro-tyrosine formation. GSNO showed protective role in iNOS/nitrosative stress mediated calpain/tau pathologies (Won et al., 2015). GSNO reduced the A β and ICAM-1/VCAM-1 levels in the rat brain following

chronic cerebral hypoperfusion. Besides, GSNO treatment induces other beneficial effects; these include decreased cytokine-induced proinflammatory response (viz. activation of NF κ B and STAT3) and expression of ICAM-1 and VCAM-1 in the endothelial cells. Furthermore, experiments in primary rat neuron cell culture confirmed that GSNO decreases A β through inhibition of the β -secretase activity (Won et al., 2013).

L-carnitine

There is impaired endothelial function in vascular diseases. The dysfunction develops owing to oxidative stress; hence, antioxidant can be of clinical advantage. The effectiveness of antioxidant L-carnitine was studied in TNF- α -stimulated human umbilical vein endothelial cells in vitro. Following antioxidant treatment, mitochondrial β -oxidation was restored; also, increased cell adhesion molecule and Nox4 expression, leukocyte adhesion, and inflammatory cytokine secretion were counteracted. Further work has shown that endothelial inflammation and oxidative stress are Nox4-induced (Scioli et al., 2014).

28 days after the induction of chronic hypoperfusion, rats were treated with (or without) L-carnitine. L-carnitine had the following beneficial effects. It reduced PTEN (phosphorylated phosphatase tensin homolog deleted on chromosome 10) and increased phosphorylated Akt and mammalian target of rapamycin (mTOR) (Ueno et al., 2015). Further, L-carnitine treatment in the hypoperfused rats reduced lipid peroxidation and oxidative DNA damage but increased myelin sheath thickness. Hence, L-carnitine has been shown to be effective in regulating the PTEN/Akt/mTOR signaling pathway, and enhancing axonal plasticity; it also ameliorates oxidative stress and increases myelination of axons (Ueno et al., 2015). This study also documented that L-carnitine ameliorates white matter pathology and cognitive decline in chronic hypoperfusion.

Simvastatin

It is noteworthy that simvastatin treatment of APP(Swe, Ind) mice fully restored NO activity in their vessel walls and ameliorated dilatory deficits, but not the impaired hyperemic response to whisker stimulation (Papadopoulos et al., 2014; Tong and Hamel, 2015).

L-arginine, Clazosentan, and Bosentan

L-arginine is the substrate for nitric oxide synthase. Both clazosentan and bosentan are the antagonist of endothelin-1. The administration of the above compounds can ameliorate vasoconstriction and reduce hypoperfusion (Fabricius et al., 1995; Scheckenbach et al., 2006; Schubert et al., 2008; Kreipke et al., 2011; D'haeseleer et al., 2013).

4.3 Nutraceutical Approach

Several studies have emphasized the use of multi-nutrient dietary interventions in both prevention and treatment of AD. The effectiveness of diets is based on specific nutrients provided. These diets claim to attenuate neurodegenerative and enhance neuronal maintenance/repair.

Fortasyn® Connect (FC)

Male A β PP-PS1 mice (and wild-type littermates) were fed the Fortasyn® Connect (FC) diet (that contains cofactors for membrane synthesis). FC is enriched with the omega-3 fatty acids docosahexaenoic acid (DHA),

eicosapentaenoic acid (EPA), uridine monophosphate, phospholipids, choline, folic acid, vitamins, and antioxidants. This diet is claimed to ameliorate synapse loss and synaptic dysfunction in AD. The FC diet was found to restore neurogenesis in A β PP-PS1 mice and decrease the anxiety-related behavior (Jansen et al., 2013). APPswe/PS1dE9 mice on control diet showed hypoperfusion, axonal disconnection and neuronal loss (as found in AD). However, after feeding FC diet, there was reduced water diffusivity and increased cortical CBF in the dentate gyrus and cortical regions of these mice (Zerbi et al., 2014). The beneficial effects of FC diet have been confirmed in terms of decreasing A β and amyloid plaque burden in the hippocampus of these transgenic animals (Broersen et al., 2013).

Rutin and Polyphenols

Rutin is a biologically active flavonoid; its antioxidant and anti-inflammatory properties protect the brain. Rutin has shown multi-faceted therapeutic benefits including the alleviation of cerebral hypoperfusion (Qu et al., 2014).

Polyphenols are widespread natural compounds found in vegetables, fruits, grains, bark, roots, tea, and wine.

Most polyphenols possess antioxidant, anti-inflammatory, and anti-apoptotic properties; they also have protective effects on mitochondria, glutamate uptake, regulation of intracellular calcium levels, and ischemic injury (Panickar and Jang, 2013). Studies have documented that green tea polyphenols (GTP) reduce BBB permeability after ischemia. GTP reversed the opening of tight junction (TJ) barrier, decreased mRNA and lowered protein expression of claudin-5, occludin, and ZO-1 in microvessel fragments after hypoperfusion. Hence, GTP functions as a neuroprotective agent in cerebral ischemia (Liu et al., 2013).

Ligustilide

Ligustilide (LIG) is an interesting nutraceutical. It is a lipophilic component of Danggui – a Chinese Angelica root, *Radix Angelica sinensis*. Rats having Chronic cerebral hypoperfusion (induced surgically) were treated with LIG (80mg/kg, oral). LIG prevented dendritic damage, neuronal apoptosis, and neuronal loss in the parietal cortex and hippocampus. LIG also inhibited astrocytic proliferation following hypoperfusion. LIG, therefore, appears valuable in imparting beneficial neuroprotective effects in chronic cerebral hypoperfusion injury (Feng et al., 2012).

Souvenaid

Souvenaid® is a medical food product that has components found in Fortasyn® Connect (FC) diet, with modifications. Synaptic loss is integral to cognitive deficits in AD; therefore, Souvenaid has been developed over 12 years to affect synaptic integrity and function in AD. Two randomised, double-blind, controlled trials (duration 12 and 24 weeks) in AD patients (not treated with acetylcholinesterase inhibitors and/or memantine) have found Souvenaid® to be effective in improving episodic memory performance (de Waal et al., 2014; Pardini et al., 2015; Ritchie et al., 2014). Given the above beneficial effects, it is not unreasonable to expect Souvenaid® to be protective in cerebral hypoperfusion also.

5. Concluding Remarks

Chronic cerebral hypoperfusion noted in many medical conditions in the elderly stimulates several pathologies including glucose hypometabolism, WM Lesions, and cognitive impairment. Chronic hypoperfusion in

conjunction with inflammation, ONS, A β accumulation, and tau hyperphosphorylation promotes synaptic dysfunction and neuronal degeneration/loss – leading to gray and white matter atrophy. These pathological events eventually lead to cognitive decline in the vulnerable aged with comorbid conditions (Zhao and Gong, 2015; Zhu et al., 2007).

There is a close relationship between rCBF and metabolic activity in brain regions. Thus, rCBF is closely coupled to CMRglc, and CMRglc reflects neuronal activity (see above). Studies in normal aged humans have found age-related decreases in brain glucose metabolism. In gray and white matter areas CBF and blood volume (CBV) decrease with age approximately 0.50% per year (Leenders et al., 1990). There is age-related decline also in CMRO₂ (Takada *et al.*, 1992). The decrease in CBF and CMRO₂ in gray matter is about 18% and 17% respectively in aging (Pantano et al., 1984). Similarly, in the aged rhesus monkeys (roughly equivalent to 54–75 yo humans), correlated decreases occur in both CMRglc and CBF in many brain regions including frontal, temporal, and occipital cortices, and cerebellum, hippocampus, and striatum (Noda et al., 2002). Several medical conditions discussed above may synergistically upregulate hypoperfusion and hypometabolism. For example, higher peripheral insulin resistance even in cognitively normal late middle-aged (60 yo) persons was associated with lower global glucose metabolism and lower CMRglc in the frontal, parietal, and temporal lobes (Willette et al., 2005). In hypertensive individuals, cerebral microbleeds (related to CAA) may be associated with significantly reduced resting-state CBF in multiple brain regions with the highest decrease in the parietal cortex and precuneus (Gregg et al., 2015). The above mentioned pathological stigmata have been described in a diverse range of medical conditions (see above)

A β overexpression (*e.g.* in CAA) impairs CBF in critical brain regions including the entorhinal, temporal, parietal and precuneus. Chronic hypoperfusion, therefore, is contributory in inducing neuronal injury/neurodegeneration and promoting cognitive decline/AD (Daultazai; 2013a, 2013b, 2014, 2015b-d; Mattson et al., 2014). Strategies including pharmacotherapy and nutraceutical consumption described here may be neuroprotective and attenuate chronic hypoperfusion. The above discussion on the multi-faceted origin of hypoperfusion, therefore, calls for early, sustained, and aggressive intervention through exercise, lifestyle changes, pharmacotherapy, and dietary supplementation.

Finally, there are convincing and accumulating studies that cerebral hypoperfusion is correlated with cognitive impairment and neurodegenerative disease (Bennett et al., 1998; Dardiotis et al., 2012; de la Torre, 2012; Daultazai, 2013; Abete et al., 2014; Toda et al., 2014). Furthermore, data from experimental models of chronic hypoperfusion clearly corroborate an association of cerebral hypoperfusion with cognitive dysfunctions (Ni et al., 1994; Sarti et al., 2002; Farkas et al., 2007; Cechetti et al., 2010).

Figure Legend

Figure 1. Schematic representation of the pathogenesis of cognitive decline in aging and AD.

Several comorbid conditions in aging are associated with the risk of cerebral hypoperfusion and glucose hypometabolism. Thus, multifactorial modulators have the potential to trigger inflammatory and oxidative stress responses that may give rise to dysregulation of homeostasis. Cerebral microvascular pathology deposits A β in the walls of cerebral vessels which is a common cause of cerebral amyloid angiopathy (CAA). Consequently, dysfunctional neurovascular unit alters CBF regulation, promoting a secondary cascade of events. Endothelin-1 (released by the endothelium) activity - a potent vasoconstrictor is upregulated. Decreased endothelial NO (a major vasodilator) plays an important role in modulating APP and upregulating A β expression within the cerebrovasculature. The chronic activation of microglia is also associated with A β increase. Besides, dysfunctional BBB contributes to an increase in cerebral neurotoxic substances, leukocytic migration across the BBB, and the development of neurodegeneration.

CONFLICT OF INTEREST STATEMENT

The author has no conflicts of interest to declare.

References

- Aanerud J, Borghammer P, Chakravarty MM, Vang K, Rodell AB, Jónsdóttir KY, Møller A, Ashkanian M, Vafaee MS, Iversen P, Johannsen P, Gjedde A. 2012. J Cereb Blood Flow Metab 32: 1177– 1187.
- Abdul Muneer PM, Alikunju S, Szlachetka AM, Haorah J. 2011a. Inhibitory effects of alcohol on glucose transport across the blood-brain barrier lead to neurodegeneration: Preventive role of acetyl-L-carnitine. Psychopharmacology (Berl) 214:707-718.
- Abdul Muneer PM, Alikunju S, Szlachetka AM, Mercer AJ, Haorah J. 2011b. Ethanol impairs glucose uptake by human astrocytes and neurons: protective effects of acetyl-L- carnitine. Int J Physiol Pathophysiol Pharmacol 3:48-56.
- Abete P, Della-Morte D, Gargiulo G, Basile C, Langellotto A, Galizia G, Testa G, Canonico V, Bonaduce D, Cacciatore F. 2014. Cognitive impairment and cardiovascular diseases in the elderly. A heart-brain continuum hypothesis. Ageing Res Rev 18:41-52.
- Akchiche N, Bossenmeyer-Pourie C, Kerek R, Martin N, Pourie G, Koziel V, Helle D, Alberto JM, Ortiou S, Camadro JM, Léger T, Guéant JL, Daval JL. 2012. Homocysteinylation of neuronal proteins contributes to folate deficiency-associated alterations of differentiation, vesicular transport, and plasticity in hippocampal neuronal cells. FASEB J 26:3980-3992.
- Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. 2002. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am J Psychiatry 159:738-745.
- Allan CL, Zsoldos E, Filippini N, Sexton CE, Topiwala A, Valkanova V, Singh-Manoux A, Tabák AG, Shipley MJ, Mackay C, Ebmeier KP, Kivimäki M. 2015. Lifetime hypertension as a predictor of brain structure in older adults: cohort study with a 28-year follow-up. Br J Psychiatry 206:308-315.
- Allen PA, Kaut KP, Lord RG, Hall RJ, Grabbe JW, Bowie T. 2005. An emotional mediation theory of differential age effects in episodic and semantic memories. Exp Aging Res 31:355-91.
- Almendros I, Farré R, Planas AM, Torres M, Bonsignore MR, Navajas D, Montserrat JM. 2011. Tissue oxygenation in brain, muscle, and fat in a rat model of sleep apnea: differential effect of obstructive apneas and intermittent hypoxia. Sleep 34:1127-33.

- Alosco ML, Spitznagel MB, Raz N, Cohen R, Sweet LH, Colbert LH, Josephson R, van Dulmen M, Hughes J, Rosneck J, Gunstad J. 2012. Obesity interacts with cerebral hypoperfusion to exacerbate cognitive impairment in older adults with heart failure. *Cerebrovasc Dis Extra* 2:88-98.
- Alosco ML, Brickman AM, Spitznagel MB, Griffith EY, Narkhede A, Raz N. 2013. J Clin Exp Neuropsychol 2013;35:309-318. The adverse impact of type 2 diabetes on brain volume in heart failure. *J Clin Exp Neuropsychol* 35:309-318.
- Alosco ML, Gunstad J, Jerskey BA, Xu X, Clark US, Hassenstab J, Cote DM, Walsh EG, Labbe DR, Hoge R, Cohen RA, Sweet LH. 2013. The adverse effects of reduced cerebral perfusion on cognition and brain structure in older adults with cardiovascular disease. *Brain Behav* 3:626-636.
- Alosco ML, Gunstad J, Xu X, Clark US, Labbe DR, Riskin-Jones HH, Terrero G7, Schwarz NF8, Walsh EG, Poppas A, Cohen RA, Sweet LH. 2014. The impact of hypertension on cerebral perfusion and cortical thickness in older adults. *J Am Soc Hypertens* 8:561-570.
- Alosco ML, Spitznagel MB, Gunstad J. 2014. Obesity as a risk factor for poor neurocognitive outcomes in older adults with heart failure. *Heart Fail Rev* 19:403-411.
- Alpert MA. 2001. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. *Am J Med Sci* 321: 225–236.
- Altman R, Rutledge JC. 2010. The vascular contribution to Alzheimer's disease. *Clin Sci (Lond)* 119:407-421.
- Alzheimer's Association. 2014. Alzheimer's disease facts and figures. *Alzheimers Dement* 10:e47-e92.
- Amariglio RE, Mormino EC, Pietras AC, Marshall GA, Vannini P, Johnson KA, Sperling RA, Rentz DM. 2015. Subjective cognitive concerns, amyloid- β , and neurodegeneration in clinically normal elderly. *Neurology* 85:56-62.
- Anstey K, Sargent-Cox K, Eramudugolla R, Magliano DJ, Shaw JE. 2015. Association of cognitive function with glucose tolerance and trajectories of glucose tolerance over 12 years in the AusDiab study. *Alzheimer's Research & Therapy* 7:48
- Araki T, Kato H, Inoue T, Kogure K. 1990. Regional impairment of protein synthesis following brief cerebral ischemia in the gerbil. *Acta Neuropathol* 79:501–505.
- Arzt M, Young T, Finn L, Skatrud JB, Bradley TD. 2005. Association of sleep-disordered breathing and the occurrence of stroke. *Am J Respir Crit Care Med* 172:1447–1451.
- Attems J. 2005. Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. *Acta Neuropathol.* 110:345–359.
- Ayata C, Shin HK, Dileköz E, Atochin DN, Kashiwagi S, Eikermann-Haerter K, Huang PL. 2013. Hyperlipidemia disrupts cerebrovascular reflexes and worsens ischemic perfusion defect. *J Cereb Blood Flow Metab* 33:954-962.
- Ayata C, Shin HK, Salomone S, Ozdemir-Gursoy Y, Boas DA, Dunn AK, Moskowitz MA. 2004. Pronounced hypoperfusion during spreading depression in mouse cortex. *J Cereb Blood Flow Metab* 24: 1172–1182.
- Aviv A. 2002. Telomeres, sex, reactive oxygen species, and human cardiovascular aging. *J Mol Med (Berl)* ;80:689-695.
- Ayata C, Shin HK, Salomone S, Ozdemir-Gursoy Y, Boas DA, Dunn AK, Moskowitz MA. 2004. Pronounced hypoperfusion during spreading depression in mouse cortex. *J Cereb Blood Flow Metab* 24:1172–1182.
- Azad NA, A, Bugami M, Loy-English I. 2007. Gender differences in dementia risk factors. *Gend Med* 4:120-129.
- Bälfors EM, Franklin KA. 1994. Impairment of cerebral perfusion during obstructive sleep apneas. *Am J Respir Crit Care Med* 150:1587-1591.
- Banks WA, Gray AM, Erickson MA, Salameh TS, Damodarasamy M, Sheibani N, Meabon JS, Wing EE, Morofuji Y, Cook DG, Reed MJ. 2015. Lipopolysaccharide-induced blood-brain barrier disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, and elements of the neurovascular unit. *J Neuroinflammation* 12:223.
- Baril AA, Gagnon K, Arbour C, Soucy JP, Montplaisir J, Gagnon JF, Baril AA, Gagnon K, Arbour C, Soucy JP, Montplaisir J, Gagnon JF, Gosselin N. 2015. Regional Cerebral Blood Flow during Wakeful Rest in Older Subjects with Mild to Severe Obstructive Sleep Apnea. *Sleep* 38:1439-49.

- Bartus RT. 2000. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. *Exp Neurol* 163:495-529.
- Baumann O, Walz B. 2001. Endoplasmic reticulum of animal cells and its organization into structural and functional domains. *Int Rev Cytol* 205:149-214.
- Baydas G, Reiter RJ, Akbulut M, Tuzcu M, Tamer S. 2005. Melatonin inhibits neural apoptosis induced by homocysteine in hippocampus of rats via inhibition of cytochrome c translocation and caspase-3 activation and by regulating pro- and anti-apoptotic protein levels. *Neuroscience* 135: 879-886.
- Beauchet O, Celle S, Roche F, Bartha R, Montero-Odasso M, Allali G, Annweiler C. 2013. Blood pressure levels and brain volume reduction: a systematic review and meta-analysis. *J Hypertens* 31:1502-1516.
- Beckmann N, Schuler A, Mueggler T, Meyer EP, Wiederhold KH, Staufenbiel M, Krucker T. 2003. Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease. *J Neurosci* 23:8453-8459.
- Bell RD, Zlokovic BV. 2009. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. *Acta Neuropathol* 118:103-113.
- Bench CJ, Friston KJ, Brown RG, Frackowiak RS, Dolan RJ. 1993. Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions. *Psychol Med* 23:579-590.
- Bennett SA, Tenniswood M, Chen JH, Davidson CM, Keyes MT, Fortin T, Pappas BA. 1998. Chronic cerebral hypoperfusion elicits neuronal apoptosis and behavioral impairment. *Neuroreport* 9:161-166.
- Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. 2005. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. *Neurology* 64:834-841.
- Biessels GJ, Strachan MWJ, Visseren FLJ, Kappelle LJ, Whitmer RA. 2014. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. *Lancet Diabetes Endocrinol* 2:246-255.
- Birdsill AC, Carlsson CM, Willette AA, Okonkwo OC, Johnson SC, Xu G, Oh JM, Gallagher CL, Kosciuk RL, Jonaitis EM, Hermann BP, LaRue A, Rowley HA, Asthana S, Sager MA, Bendlin BB. 2013. Low cerebral blood flow is associated with lower memory function in metabolic syndrome. *Obesity (Silver Spring)* 21:1313-1320.
- Biron KE, Dickstein DL, Gopaul R, Jefferies WA. 2011. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. *PLoS One* 6:e23789.
- Bjorklund NL, Reese LC, Sadagoparamanujam VM, Ghirardi V, Woltjer RL, Tagliatela G. 2012. Absence of amyloid β oligomers at the postsynapse and regulated synaptic Zn²⁺ in cognitively intact aged individuals with Alzheimer's disease neuropathology. *Mol Neurodegener* 7:23.
- Bjorntorp P. 2001. Do stress reactions cause abdominal obesity and comorbidities? *Obes Rev* 2: 73-86.
- Blackburn EH, Epel ES, Lin J. 2015. Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. *Science*. 350:1193-1198.
- Bouras C, Kövari E, Herrmann FR, Rivara CB, Bailey TL, von Gunten A, Hof PR, Giannakopoulos P. 2006. Stereologic analysis of microvascular morphology in the elderly: Alzheimer disease pathology and cognitive status. *J Neuropathol Exp Neurol* 65:235-244.
- Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. 2007. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. *Neurology* 68:1809-1814.
- Brkic M, Balusu S, Van Wonterghem E, Gorlé N, Benilova I, Kremer A, Van Hove I, Moons L, De Strooper B, Kanazir S, Libert C, Vandenbroucke RE. 2015. Amyloid β Oligomers Disrupt Blood-CSF Barrier Integrity by Activating Matrix Metalloproteinases. *J Neurosci* 35:12766-12778.
- Broersen LM, Kuipers AA, Balvers M, van Wijk N, Savelkoul PJ, de Wilde MC, van der Beek EM, Sijben JW, Hageman RJ, Kamphuis PJ, Kiliaan AJ. 2013. A specific multi-nutrient diet reduces Alzheimer-like pathology in young adult A β PPswe/PS1dE9 mice. *J Alzheimers Dis* 33:177-190.
- Brookmeyer R, Evans DA, Hebert L, Langa KM, Heeringa SG, Plassman BL, Kukull WA. 2011. National estimates of the prevalence of Alzheimer's disease in the United States. *Alzheimers Dement* 7:61-73.

- Brown WR, Thore CR. 2011. Review: Cerebral microvascular pathology in ageing and neurodegeneration. *Neuropathol Appl Neurobiol* 37:56-74.
- Brunelle JK, Letai A. 2009. Control of mitochondrial apoptosis by the Bcl-2 family. *J Cell Sci* 122: 437-441.
- Buckwalter M, Pepper JP, Gaertner RF, Von Euw D, Lacombe P, Wyss-Coray T. 2002. Molecular and functional dissection of TGF-beta1-induced cerebrovascular abnormalities in transgenic mice. *Ann N Y Acad Sci* 977:87-95.
- Bulbarelli A, Lonati E, Brambilla A, Orlando A, Cazzaniga E, Piazza F, Ferrarese C, Masserini M, Sancini G. 2012. A β 42 production in brain capillary endothelial cells after oxygen and glucose deprivation. *Mol Cell Neurosci* 49:415-422.
- Burgermeister P, Calhoun ME, Winkler DT, Jucker M. 2000. Mechanisms of cerebrovascular amyloid deposition. Lessons from mouse models. *Ann N Y Acad Sci* 903:307-316.
- Cai ZY, Yan Y, Sun SQ, Zhang J, Huang LG, Yan N, Wu F, Li JY. 2008. Minocycline attenuates cognitive impairment and restrains oxidative stress in the hippocampus of rats with chronic cerebral hypoperfusion. *Neurosci Bull* 24:305-313.
- Canessa N, Castronovo V, Cappa SF, Aloia MS, Marelli S, Falini A, Alemanno F, Ferini-Strambi L. 2011. Obstructive sleep apnea: brain structural changes and neurocognitive function before and after treatment. *Am J Respir Crit Care Med* 183:1419-1426.
- Canobbio I, Abubaker AA, Visconte C, Torti M, Pula G. 2015. Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer's disease. *Front Cell Neurosci* 9:65.
- Carpagnano GE, Spanevello A, Sabato R, Depalo A, Palladino GP, Bergantino L, Foschino Barbaro MP. 2010. Systemic and airway inflammation in sleep apnea and obesity: the role of ICAM-1 and IL-8. *Transl Res* 155:35-43.
- Cechetti F, Worm PV, Pereira LO, Siqueira IR, A Netto C. 2010. The modified 2VO ischemia protocol causes cognitive impairment similar to that induced by the standard method, but with a better survival rate. *Braz J Med Biol Res* 43:1178-83.
- Chen H, Liu S, Ji L, Wu T, Ma F, Ji Y, Zhou Y, Zheng M, Zhang M, Huang G. 2015. Associations between Alzheimer's disease and blood homocysteine, vitamin B12, and folate: a case-control study. *Curr Alzheimer Res* 12:88-94.
- Chen ST, Siddarth P, Ercoli LM, Merrill DA, Torres-Gil F, Small GW. 2014. Modifiable risk factors for Alzheimer disease and subjective memory impairment across age groups. *PLoS One* 9:e98630.
- Chen ZQ, Du MY, Zhao YJ, Huang XQ, Li J, Lui S, Hu JM, Sun HQ, Liu J, Kemp GJ, Gong QY. 2015. Voxel-wise meta-analyses of brain blood flow and local synchrony abnormalities in medication-free patients with major depressive disorder. *J Psychiatry Neurosci* 40:401-411.
- Chêne G, Beiser A, Au R, Preis SR, Wolf PA, Dufouil C, Seshadri S. 2015. Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. *Alzheimers Dement* 11:310-320.
- Cherbuin N, Sachdev P, Anstey KJ. 2012. Higher normal fasting plasma glucose is associated with hippocampal atrophy: The PATH Study. *Neurology* 79:1019-1026.
- Choe YM, Sohn BK, Choi HJ, Byun MS, Seo EH, Han JY, Kim YK3, Yoon EJ3, Lee JM4, Park J4, Woo JI1, Lee DY. 2014. Association of homocysteine with hippocampal volume independent of cerebral amyloid and vascular burden. *Neurobiol Aging* 35:1519-1525.
- Choi JM, Shin HK, Kim KY, Lee JH, Hong KW. 2002. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. *J Pharmacol Exp Ther* 300:787-93.
- Chung S, Yoon IY, Lee CH, Kim JW. 2013. The association of nocturnal hypoxemia with arterial stiffness and endothelial dysfunction in male patients with obstructive sleep apnea syndrome. *Respiration* 2010;79:363-369.
- Cirelli C. 2013. Sleep and synaptic changes. *Curr Opin Neurobiol* 23:841-846.
- Clausen F, Hillered L, Gustafsson J. 2011. Cerebral glucose metabolism after traumatic brain injury in the rat studied by ¹³C-glucose and microdialysis. *Acta Neurochir (Wien)* 153:653-658.
- Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W, Nebes RD, Saxton JA, Snitz BE, Aizenstein HA, Wolk DA,

- Dekosky ST, Mathis CA, Klunk WE. 2009. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. *J Neurosci* 29:14770-14778.
- Corfield DR, Meadows GE. 2006. Control of cerebral blood flow during sleep and the effects of hypoxia. *Adv Exp Med Biol* 588:65-73.
- Crane PK, Walker R, Hubbard RA, Li G, Nathan DM, Zheng H, Haneuse S, Craft S, Montine TJ, Kahn SE, McCormick W, McCurry SM, Bowen JD, Larson EB. 2013. Glucose levels and risk of dementia. *N Engl J Med* 369:540-548.
- Crews FT, Nixon K. 2009. Mechanisms of neurodegeneration and regeneration in alcoholism. *Alcohol Alcohol* 44:115-127.
- Csiszar A, Tucsek Z, Toth P, Sosnowska D, Gautam T, Koller A, Deak F, Sonntag WE, Ungvari Z. 2013. Synergistic effects of hypertension and aging on cognitive function and hippocampal expression of genes involved in β -amyloid generation and Alzheimer's disease. *Am J Physiol Heart Circ Physiol* 305:H1120-30.
- da Cunha AA, Ferreira AG, Loureiro SO, da Cunha MJ, Schmitz F, Netto CA, Wyse AT. 2012. Chronic hyperhomocysteinemia increases inflammatory markers in hippocampus and serum of rats. *Neurochem Res* 37:1660-1669.
- Daffertshofer M, Hennerici M. 1995. Cerebrovascular regulation and vasoneuronal coupling. *J Clin Ultrasound* 23:125-138.
- Daiber A, Di Lisa F, Oelze M, Kröller-Schön S, Steven S, Schulz E, Münzel T. 2015. Crosstalk of mitochondria with NADPH oxidase via reactive oxygen and nitrogen species signalling and its role for vascular function. *Br J Pharmacol* 2015 Dec 9. doi: 10.1111/bph.13403. [Epub ahead of print].
- Dardiotis E, Giamouzis G, Mastrogiannis D, Vogiatzi C, Skoularigis J, Triposkiadis F, Hadjigeorgiou GM. 2012. Cognitive impairment in heart failure. *Cardiol Res Pract* 2012:595821.
- Daulatzai MA. 2010. Early stages of pathogenesis in memory impairment during normal senescence and Alzheimer's disease. *J Alzheimers Dis* 20: 355-367.
- Daulatzai MA. 2012a. Neuroinflammation and Dysfunctional Nucleus Tractus Solitarius: Their Role in Neuropathogenesis of Alzheimer's Dementia. *Neurochem Res* 37:846-868.
- Daulatzai MA. 2012b. Quintessential Risk Factors: Their Role in Promoting Cognitive Dysfunction and Alzheimer's disease. *Neurochem Res* 37:2627-2658.
- Daulatzai MA. 2013a. Death by a Thousand Cuts in Alzheimer's disease: Hypoxia - The Prodrome. *Neurotox Res* 24:216-243.
- Daulatzai MA. 2013b. Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's Disease. *Neurotox Res* 24:407-459.
- Daulatzai MA. 2014. Obesity and Gut's Dysbiosis Promote Neuroinflammation, Cognitive Impairment, and Vulnerability to Alzheimer's disease: New Directions and Therapeutic Implications. *J Mol Genet Med* 2014:1-10.
- Daulatzai MA. 2015a. Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Dementia. *CNS & Neurological Disorders - Drug Targets* 14:110 -131.
- Daulatzai MA. 2015b. "Boomerang Neuropathology" of Late-Onset Alzheimer's Disease is shrouded in Harmful "BDDS": Breathing, Diet, Drinking, and Sleep During Aging. *Neurotox Res* 28:55-93.
- Daulatzai MA. 2015c. Olfactory dysfunction: its early temporal relationship and neural correlates in the pathogenesis of Alzheimer's disease. *J Neural Transm* 122:1475-1497.
- Daulatzai MA. 2015d. Evidence of neurodegeneration in obstructive sleep apnea: Relationship between obstructive sleep apnea and cognitive dysfunction in the elderly. *J Neurosci Res* 93:1778-1794.
- De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Klein WL. 2007. A β oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. *J Biol Chem* 282:11590-11601.
- DeGracia DJ, Montie HL. 2004. Cerebral ischemia and the unfolded protein response. *J Neurochem* 91:1-8.
- de la Torre JC, Pappas BA, Prevot V, Emmerling MR, Mantione K, Fortin T, Watson MD, Stefano GB.

2003. Hippocampal nitric oxide upregulation precedes memory loss and Abeta 1-40 accumulation after chronic brain hypoperfusion in rats. *Neurol Res* 25:635-641.
- de la Torre JC. 2012. Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. *Cardiovasc Psychiatry Neurol* 2012:367516.
- De Souza L, Smaili SS, Ureshino RP, Sinigaglia-Coimbra R, Andersen ML, Lopes GS, Tufik S. 2012. Effect of chronic sleep restriction and aging on calcium signalling and apoptosis in the hippocampus of young and aged animals. *Prog Neuropsychopharmacol Biol Psychiatry* 39:23-30.
- de Waal H, Stam CJ, Lansbergen MM, Wieggers RL, Kamphuis PJ, Scheltens P, Maestú F, van Straaten EC. 2014. The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study. *PLoS One* 9:e86558.
- Dean PJ, Sterr A. 2013. Long-term effects of mild traumatic brain injury on cognitive performance. *Front Hum Neurosci* 7:30.
- Deane R, Zlokovic BV. 2007. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. *Curr Alzheimer Res* 4:191-197.
- Debette S, Seshadri S, Beiser A, Au R, Himali JJ, Palumbo C, Wolf PA, DeCarli C. 2011. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. *Neurology* 77:461-468.
- D'haeseleer M, Beelen R, Fierens Y, Cambron M, Vanbinst AM, Verborgh C, Demey J, De Keyser J. 2013. Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1. *Proc Natl Acad Sci USA* 110:5654-5658.
- Dehlendorff C, Andersen KK, Olsen TS. 2014. Body Mass Index and Death by Stroke: No Obesity Paradox. *JAMA Neurol* 71:978-984.
- Del Sole A, Clerici F, Chiti A, Lecchi M, Mariani C, Maggiore L, Mosconi L, Lucignani G. 2008. Individual cerebral metabolic deficits in Alzheimer's disease and amnesic mild cognitive impairment: an FDG PET study. *Eur J Nucl Med Mol Imaging* 35:1357-1366.
- Del Tredici K, Braak H. 2008. Neurofibrillary changes of the Alzheimer type in very elderly individuals: neither inevitable nor benign: Commentary on "No disease in the brain of a 115-year-old woman". *Neurobiol Aging* 29:1133-1136.
- De Reuck JL, Cordonnier C, Deramecourt V, Auger F, Durieux N, Bordet R, Maurage CA, Leys D, Pasquier F. 2013. Microbleeds in postmortem brains of patients with Alzheimer disease: a T2*-weighted gradient-echo 7.0 T magnetic resonance imaging study. *Alzheimer Dis Assoc Disord* 27:162-167.
- Desai TR, Leeper NJ, Hynes KL, Gewertz BL. 2002. Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. *J Surg Res* 104:118-123.
- Devanand DP, Liu X, Tabert MH, Pradhaban G, Cuasay K, Bell K, de Leon MJ, Doty RL, Stern Y, Pelton GH. 2008. Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. *Biol Psychiatry* 64:871-879.
- Dickerson BC, Feczko E, Augustinack JC, Pacheco J, Morris JC, Fischl B, Buckner RL. 2009. Differential effects of aging and Alzheimer's disease on medial temporal lobe cortical thickness and surface area. *Neurobiol Aging* 30:432-440.
- Dickstein DL, Walsh J, Brautigam H, Stockton SD Jr, Gandy S, Hof PR. 2010. Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. *Mt Sinai J Med* 77:82-102.
- Diemer NH, Valente E, Bruhn T, Berg M, Jürgensen MB, Johansen FF. 1993. Glutamate receptor transmission and ischemic nerve cell damage: evidence for involvement of excitotoxic mechanisms. *Prog Brain Res* 96:105-123.
- Dik MG, Jonker C, Comijs HC, Deeg DJ, Kok A, Yaffe K, Penninx BW. 2007. Contribution of metabolic syndrome components to cognition in older individuals. *Diabetes Care* 30:2655-2660.
- Di Marco LY, Venneri A, Farkas E, Evans PC, Marzo A, Frangi AF. 2015. Vascular dysfunction in the pathogenesis of Alzheimer's disease – A review of endothelium-mediated mechanisms and ensuing vicious circles. *Neurobiol Dis* 82:593-606.

- Ding J, Sigurdsson S, Garcia M, Phillips CL, Eiriksdottir G, Gudnason V, van Buchem MA, Launer LJ. 2015. Risk Factors Associated With Incident Cerebral Microbleeds According to Location in Older People: The Age, Gene/Environment Susceptibility (AGES)–Reykjavik Study. *JAMA Neurol* 72:682-688.
- Dohmen C, Sakowitz OW, Fabricius M, Bosche B, Reithmeier T, Ernestus RI, Brinker G, Dreier JP, Woitzik J, Strong AJ, Graf R. 2008. Spreading depolarizations occur in human ischemic stroke with high incidence. *Ann Neurol* 63: 720–728.
- Doi K, Suzuki Y, Nakao A, Fujita T, Noiri E. 2004. Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney. *Kidney Int* 65:1714-23.
- Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, Smith AD. 2013. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. *Proc Natl Acad Sci U S A* 110:9523-9528.
- Dougherty MK, Morrison DK. 2004. Unlocking the code of 14-3-3. *J Cell Sci* 117: 1875–1884.
- Dufouil C, Seshadri S, Chêne G. 2014. Cardiovascular risk profile in women and dementia. *J Alzheimers Dis* 42 Suppl 4:S353-S363.
- Duron E, Hanon O. 2008. Hypertension, cognitive decline and dementia. *Arch Cardiovasc Dis* 101:181-189.
- Efimova Iu, Belokopytova NV, Triss SV, Lishmanov IuB. 2007. Cerebral perfusion in patients with arterial hypertension associated with type 2 diabetes. *Klin Med (Mosk)* 85:33-37.
- Ehrlich D, Pirchl M, Humpel C. 2012. Effects of long-term moderate ethanol and cholesterol on cognition, cholinergic neurons, inflammation, and vascular impairment in rats. *Neuroscience* 205:154-166.
- Emmrich JV, Ejaz S, Neher JJ, Williamson DJ, and Baron J-C. 2015. Regional distribution of selective neuronal loss and microglial activation across the MCA territory after transient focal ischemia: quantitative versus semiquantitative systematic immunohistochemical assessment. *Cereb Blood Flow Metab* 35: 20–27.
- Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Långström B, Nordberg A. 2006. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. *Brain* 129:2856-2866.
- Erten-Lyons D, Woltjer RL, Dodge H, Nixon R, Vorobik R, Calvert JF, Leahy M, Montine T, Kaye J. 2009. Factors associated with resistance to dementia despite high Alzheimer disease pathology. *Neurology* 72:354–360.
- Fabricius M, Akgoren N, Lauritzen M. 1995. Arginine-nitric oxide pathway and cerebrovascular regulation in cortical spreading depression. *Am J Physiol* 269:H23–H29.
- Fabricius M, Fuhr S, Bhatia R, Boutelle M, Hashemi P, Strong AJ, Lauritzen M. 2006. Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex. *Brain* 129: 778–790.
- Fakhran S, Yaeger K, Alhilali L. 2013. Symptomatic white matter changes in mild traumatic brain injury resemble pathologic features of early Alzheimer dementia. *Radiology* 269:249–257.
- Farkas E, Luiten PG. 2001. Cerebral microvascular pathology in aging and Alzheimer's disease. *Prog Neurobiol* 64:575-611.
- Farkas E, Luiten PG, Bari F. 2007. Permanent, bilateral common carotid artery occlusion in the rat: a model for chronic cerebral hypoperfusion-related neurodegenerative diseases. *Brain Res Rev* 54:162-180.
- Feng Z, Lu Y, Wu X, Zhao P, Li J, Peng B, Qian Z, Zhu L. 2012. Ligustilide alleviates brain damage and improves cognitive function in rats of chronic cerebral hypoperfusion. *J Ethnopharmacol* 144:313-321.
- Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussà F. 2004. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. *Brain Pathol* 14:11–20.
- Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. 2005. Global prevalence of dementia: a Delphi consensus study. *Lancet* 366:2112–2117.
- Feuerstein D, Manning A, Hashemi P, Bhatia R, Fabricius M, Tolias C, Ervine M, Strong AJ, Boutelle

- MG. 2010. Dynamic metabolic response to multiple spreading depolarizations in patients with acute brain injury: an online microdialysis study. *J Cereb Blood Flow Metab* 30: 1343–1355.
- Feuerstein D, Takagaki M, Gramer M, Manning A, Endepols H, Vollmar S, Yoshimine T, Strong AJ, Graf R, Backes H. 2014. Detecting tissue deterioration after brain injury: regional blood flow level versus capacity to raise blood flow. *J Cereb Blood Flow Metab* 34: 1117–1127.
- Firbank MJ, Narayan SK, Saxby BK, Ford GA, O'Brien JT. 2010. Homocysteine is associated with hippocampal and white matter atrophy in older subjects with mild hypertension. *Int Psychogeriatr* 22:804–811.
- Firbank MJ, Wiseman RM, Burton EJ, Saxby BK, O'Brien JT, Ford GA. 2007. Brain atrophy and white matter hyperintensity change in older adults and relationship to blood pressure. *Brain atrophy, WMH change and blood pressure. J Neurol* 254:713–721.
- Foley AM, Ammar ZM, Lee RH, Mitchell CS. 2015. Systematic review of the relationship between amyloid- β levels and measures of transgenic mouse cognitive deficit in Alzheimer's disease. *J Alzheimers Dis* 44:787–795.
- Ford ES, Giles WH, Dietz WH. 2002. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA* 287:356–359.
- Forsberg A, Engler H, Blomquist G, Långström B, Nordberg A. 2012. The use of PIB-PET as a dual pathological and functional biomarker in AD. *Biochim Biophys Acta* 1822:380–385.
- Foster GE, Brugniaux JV, Pialoux V, Duggan CT, Hanly PJ, Ahmed SB, Poulin MJ. 2009. Cardiovascular and cerebrovascular responses to acute hypoxia following exposure to intermittent hypoxia in healthy humans. *J Physiol* 587: 3287–3299.
- Foster GE, Hanly PJ, Ostrowski M, Poulin MJ. 2007. Effects of continuous positive airway pressure on cerebral vascular response to hypoxia in patients with obstructive sleep apnea. *Am J Respir Crit Care Med* 175:720–725.
- Fotinos AF, Snyder AZ, Gorton LE, Morris JC, Buckner RL. 2005. Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. *Neurology* 64:1032–1039.
- Freeman LR, Granholm AC. 2012. Vascular changes in rat hippocampus following a high saturated fat and cholesterol diet. *J Cereb Blood Flow Metab* 32:643–653.
- Freeman LR, Keller JN. 2012. Oxidative stress and cerebral endothelial cells: regulation of the blood-brain-barrier and antioxidant-based interventions. *Biochim Biophys Acta* 1822:822–829.
- Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM. 2005. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. *J Neurosci* 25:2803–2810.
- Fukazawa R, Hanyu H, Sato T, Shimizu S, Koyama S, Kanetaka H, Sakurai H, Iwamoto T. 2013. Subgroups of Alzheimer's disease associated with diabetes mellitus based on brain imaging. *Dement Geriatr Cogn Disord* 35:280–290.
- Furtner M, Staudacher M, Frauscher B, Brandauer E, Esnaola y Rojas MM, Gschliesser V, Poewe W, Schmidauer C, Ritsch-Marte M, Högl B. 2009. Cerebral vasoreactivity decreases overnight in severe obstructive sleep apnea syndrome: a study of cerebral hemodynamics. *Sleep Med* 10:875–881.
- Furuta S, Ohta S, Hatakeyama T, Nakamura K, Sakaki S. 1993. Recovery of protein synthesis in tolerance-induced hippocampal CA1 neurons after transient forebrain ischemia. *Acta Neuropathol* 86:329–336.
- Gajavelli S, Kentaro S, Diaz J, Yokobori S, Spurlock M, Diaz D, Jackson C, Wick A, Zhao W, Leung LY, Shear D, Tortella F, Bullock MR. Glucose and oxygen metabolism after penetrating ballistic-like brain injury. 2015. *J Cereb Blood Flow Metab* 35:773–780.
- Gazdzinski S, Millin R, Kaiser LG, Durazzo TC, Mueller SG, Weiner MW, Meyerhoff DJ. 2010. BMI and neuronal integrity in healthy, cognitively normal elderly: a proton magnetic resonance spectroscopy study. *Obesity (Silver Spring)* 18:743–748.
- Giannakopoulos P, Gold G, Kövari E, von Gunten A, Imhof A, Bouras C, Hof PR. 2007. Assessing the

- cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience. *Acta Neuropathol (Berl)* 113:1-12.
- Glodzik L, Mosconi L, Tsui W, de Santi S, Zinkowski R, Pirraglia E, Rich KE, McHugh P, Li Y, Williams S, Ali F, Zetterberg H, Blennow K, Mehta P, de Leon MJ. 2012. Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly. *Neurobiol Aging* 33:1215-1227.
- Goedert M. 1993. Tau protein and the neurofibrillary pathology of Alzheimer's disease. *Trends Neurosci* 16:460-465.
- Gold G, Kövari E, Herrmann FR, Canuto A, Hof PR, Michel JP, Bouras C, Giannakopoulos P. 2005. Cognitive consequences of thalamic, basal ganglia, and deep white matter lacunes in brain aging and dementia. *Stroke* 36:1184-1188.
- Golding EM, Robertson CS, Bryan RM Jr. 1999. The consequences of traumatic brain injury on cerebral blood flow and autoregulation: a review. *Clin Exp Hypertens* 21:299-332.
- Gorlach A, Klappa P, Kietzmann T. 2006. The endoplasmic reticulum: folding, calcium homeostasis, signaling, and redox control. *Antioxid Redox Signal* 8:1391-1418.
- Grammas P. 2000. A damaged microcirculation contributes to neuronal cell death in Alzheimer's disease. *Neurobiol Aging* 21:199-205.
- Grammas P, Ovase R. 2001. Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. *Neurobiol Aging* 22:837-842.
- Grammas P, Yamada M, Zlokovic B. 2002. The cerebrovasculature: a key player in the pathogenesis of Alzheimer's disease. *J Alzheimers Dis* 4:217-223.
- Grammas P, Samany PG, Thirumangalakudi L. 2006. Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis. *J Alzheimers Dis* 9:51-58.
- Gregg NM, Kim AE, Gurol ME, Lopez OL, Aizenstein HJ, Price JC, Mathis CA4, James JA, Snitz BE, Cohen AD, Kamboh MI, Minhas D, Weissfeld LA, Tamburo EL, Klunk WE. 2015. Incidental Cerebral Microbleeds and Cerebral Blood Flow in Elderly Individuals. *JAMA Neurol* 72:1021-1028.
- Gregoire SM, Charidimou A, Gadapa N, Dolan E, Antoun N, Peeters A, Vandermeeren Y, Laloux P, Baron JC, Jäger HR, Werring DJ. 2011. Acute ischaemic brain lesions in intracerebral haemorrhage: multicentre cross-sectional magnetic resonance imaging study. *Brain* 134: 2376-2386.
- Gupta AK, Rayussin E, Johannsen DL, Stull AJ, Cefalu WT, Johnson WD. 2012. Endothelial Dysfunction: An Early Cardiovascular Risk Marker in Asymptomatic Obese Individuals with Prediabetes. *Br J Med Med Res* 2:413-423.
- Gustafson D, Lissner L, Bengtsson C, Bjorkelund C, Skoog I. 2004. A 24-year follow-up of body mass index and cerebral atrophy. *Neurology* 63: 1876-1881.
- Haight TJ, Bryan RN, Erus G, Davatzikos C, Jacobs DR, D'Esposito M, Lewis CE5, Launer LJ. 2015. Vascular risk factors, cerebrovascular reactivity, and the default-mode brain network. *Neuroimage* 115:7-16.
- Hallam KM, Li Q, Ananthakrishnan R, Kalea A, Zou YS, Vedantham S, Schmidt AM, Yan SF, Ramasamy R. 2010. Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats. *Aging Cell* 9:776-784.
- Hamel E. 2015. Cerebral circulation: function and dysfunction in Alzheimer's disease. *J Cardiovasc Pharmacol* 65:317-324.
- Handa RK, DeJoseph MR, Singh LD, Hawkins RA, Singh SP. 2000. Glucose transporters and glucose utilization in rat brain after acute ethanol administration. *Metab Brain Dis* 15:211-222.
- Haorah J, Heilman D, Knipe B, Chrastil J, Leibhart J, Ghorpade A, Miller DW, Persidsky Y. 2005a. Ethanol-induced activation of myosin light chain kinase leads to dysfunction of tight junctions and blood-brain barrier compromise. *Alcohol Clin Exp Res* 29:999-1009.
- Haorah J, Knipe B, Leibhart J, Ghorpade A, Persidsky Y. 2005b. Alcohol-induced oxidative stress in

- brain endothelial cells causes blood–brain barrier dysfunction. *J Leukoc Biol* 78:1223–1232.
- Haorah J, Ramirez SH, Schall K, Smith D, Pandya R, Persidsky Y. 2007. Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood–brain barrier dysfunction. *J Neurochem* 101:566–576.
- Haorah J, Ramirez SH, Floreani N, Gorantla S, Morsey B, Persidsky Y. 2008a. Mechanism of alcohol-induced oxidative stress and neuronal injury. *Free Radic Biol Med* 45:1542–1550.
- Haorah J, Schall K, Ramirez SH, Persidsky Y. 2008b. Activation of protein tyrosine kinases and matrix metalloproteinases causes blood–brain barrier injury: novel mechanism for neurodegeneration associated with alcohol abuse. *Glia* 56:78–88.
- Harris JL, Yeh HW, Choi IY, Lee P, Berman NE, Swerdlow RH, Craciunas SC, Brooks WM. 2012. Altered neurochemical profile after traumatic brain injury: (1)H-MRS biomarkers of pathological mechanisms. *J Cereb Blood Flow Metab* 32:2122–2134.
- Hartings JA, Watanabe T, Bullock MR, Okonkwo DO, Fabricius M, Woitzik J, Dreier JP, Puccio A, Shutter LA, Pahl C, Strong AJ. 2011. Spreading depolarizations have prolonged direct current shifts and are associated with poor outcome in brain trauma. *Brain* 134: 1529–1540.
- Hartz AM, Bauer B, Soldner EL, Wolf A, Boy S, Backhaus R, Mihaljevic I, Bogdahn U, Klünemann HH, Schuierer G, Schlachetzki F. 2012. Amyloid- β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. *Stroke* 43:514–523.
- Hawkins BT, Davis TP. 2005. The blood-brain barrier/neurovascular unit in health and disease. *Pharmacol Rev* 57:173–185.
- He J, Hsueh H, He Y, Kastin AJ, Wang Y, Pan W. 2014. Sleep restriction impairs blood-brain barrier function. *J Neurosci* 34: 14697–14706.
- Hedman AM, van Haren NE, Schnack HG, Kahn RS, Hulshoff Pol HE. 2012. Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies. *Hum Brain Mapp* 33:1987–2002.
- Herholz K, Carter SF, Jones M. 2007. Positron emission tomography imaging in dementia. *Br J Radiol* 80:S160–167.
- Heye AK, Culling RD, Valdés Hernández Mdel C, Thrippleton MJ, Wardlaw JM. 2014. Assessment of blood-brain barrier disruption using dynamic contrast-enhanced MRI. A systematic review. *Neuroimage Clin* 6:262–274.
- Ho AJ, Raji CA, Becker JT, Lopez OL, Kuller LH, Hua X, Lee S, Hibar D, Dinov ID, Stein JL, Jack CR Jr, Weiner MW, Toga AW, Thompson PM. 2010. Obesity is linked with lower brain volume in 700 AD and MCI patients. *Neurobiol Aging* 31:1326–1339.
- Ho PI, Collins SC, Dhitavat S, Ortiz D, Ashline D, Rogers E, Shea TB. 2001. Homocysteine potentiates β -amyloid neurotoxicity: role of oxidative stress. *J Neurochem* 78: 249–253.
- Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, Ferran LJ Jr, Kohl B, Rao V, Kisiel W, Stern DM, Schmidt AM. 2001. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. *J Clin Invest* 107:675–683.
- Holland PR, Searcy JL, Salvadores N, Scullion G, Chen G, Lawson G, Scott F, Bastin ME, Ihara M, Kalaria R, Wood ER, Smith C, Wardlaw JM, Horsburgh K. 2015. Gliovascular disruption and cognitive deficits in a mouse model with features of small vessel disease. *J Cereb Blood Flow Metab* 35:1005–1014.
- Hong KW, Lee JH, Kima KY, Park SY, Lee WS. 2006. Cilostazol: therapeutic potential against focal cerebral ischemic damage. *Curr Pharm Des* 12:565–573.
- Hoozemans JJM, van Haastert ES, Nijholt DAT, Rozemuller AJM, Eikelenboom P, Scheper W. 2009. The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. *Am J Pathol* 174:1241–1251.
- Hosoi M, Hori K, Konishi K, Tani M, Tomioka H, Kitajima Y, Akashi N, Inamoto A, Kurosawa K, Yuda H, Hanashi T, Ouchi H, Hachisu M. 2015. Pharmacotherapy for Neurocognitive Disorders Based on the Hypothesis of Endogenous Appearance of Anticholinergic Activity. *Neurodegener Dis* 15:157–161.

- Hughes TM, Craft S, Lopez OL. 2015. Review of 'the potential role of arterial stiffness in the pathogenesis of Alzheimer's disease. *Neurodegener Dis Manag* 5:121-135.
- Hunt A, Schönknecht P, Henze M, Seidl U, Haberkorn U, Schröder J. 2007. Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease. *Psychiatry Res* 155:147-154.
- Hunter JM, Kwan J, Malek-Ahmadi M, Maarouf CL, Kokjohn TA, Belden C, Sabbagh MN, Beach TG, Roher AE. 2012. Morphological and pathological evolution of the brain microcirculation in aging and Alzheimer's disease. *PLoS One* 7:e36893.
- Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, Tang G, Wang B, Chen D, He M, Fu J, Cai Y, Shi X, Zhang Y, Cui Y, Sun N, Li X, Cheng X, Wang J, Yang X, Yang T, Xiao C, Zhao G, Dong Q, Zhu D, Wang X, Ge J, Zhao L, Hu D, Liu L, Hou FF. 2015. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. *JAMA* 313:1325-1335.
- Hwamee Oh, Cindee Madison, Sylvia Villeneuve, Candace Markley, and William J. Jagust. 2014. Association of Gray Matter Atrophy with Age, β -Amyloid, and Cognition in Aging. *Cereb. Cortex* 24: 1609-1618.
- Ishibashi K, Kawasaki K, Ishiwata K, Ishii K. 2015. Reduced uptake of ^{18}F -FDG and ^{15}O -H $_2\text{O}$ in Alzheimer's disease-related regions after glucose loading. *J Cereb Blood Flow Metab* 35: 1380-1385.
- Ishii H, Ishikawa H, Meguro K, Tashiro M, Yamaguchi S. 2009. Decreased cortical glucose metabolism in converters from CDR 0.5 to Alzheimer's disease in a community: the Osaki-Tajiri Project. *Int Psychogeriatr* 21:148-156.
- Iacono D, O'Brien R, Resnick SM, Zonderman AB, Pletnikova O, Rudow G, An Y, West MJ, Crain B, Troncoso JC. 2008. Neuronal hypertrophy in asymptomatic Alzheimer disease. *J Neuropathol Exp Neurol* 67:578-589.
- Ito S, Provini L, Cherubini E. 1991. L-homocysteic acid mediates synaptic excitation at NMDA receptors in the hippocampus. *Neurosci Lett* 124:157-161.
- Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC. 2008. ^{11}C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnesic mild cognitive impairment. *Brain* 131:665-680.
- Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC. 2009. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. *Brain* 132:1355-1365.
- Jack CR Jr, Wiste HJ, Weigand SD, Knopman DS, Vemuri P, Mielke MM, Lowe V, Senjem ML, Gunter JL, Machulda MM, Gregg BE, Pankratz VS, Rocca WA, Petersen RC. 2015. Age, Sex, and APOE $\epsilon 4$ Effects on Memory, Brain Structure, and β -Amyloid Across the Adult Life Span. *JAMA Neurol* 72:511-519.
- Jagust WJ, Seab JP, Huesman RH, Valk PE, Mathis CA, Reed BR, Coxson PG, Budinger TF. 1991. Diminished glucose transport in Alzheimer's disease: dynamic PET studies. *J Cereb Blood Flow Metab* 11:323-330.
- Jalloh I, Carpenter KL, Helmy A, Carpenter TA, Menon DK, Hutchinson PJ. 2015. Glucose metabolism following human traumatic brain injury: methods of assessment and pathophysiological findings. *Metab Brain Dis* 30:615-632.
- Janota C, Lemere CA, Brito MA. 2015. Dissecting the Contribution of Vascular Alterations and Aging to Alzheimer's Disease. *Mol Neurobiol* 2015 Jul 5. [Epub ahead of print].
- Jansen D, Zerbi V, Arnoldussen IA, Wiesmann M, Rijpma A, Fang XT, Dederen PJ, Mutsaers MP, Broersen LM, Lütjohann D, Miller M, Joosten LA, Heerschap A, Kiliaan AJ. 2013. Effects of specific multi-nutrient enriched diets on cerebral metabolism, cognition, and neuropathology in A β PPswe-PS1dE9 mice. *PLoS One* 8:e75393.
- Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ. 2015. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *JAMA* 313:1924-1938.
- Jellinger KA. 2002. Alzheimer disease and cerebrovascular pathology: an update. *J Neural Transm* 109:813-836.

- Jellinger KA. 2007. The enigma of vascular cognitive disorder and vascular dementia. *Acta Neuropathol* 113:349–388.
- Jeynes B, Provias J. 2006. The possible role of capillary cerebral amyloid angiopathy in Alzheimer lesion development: a regional comparison. *Acta Neuropathol (Berl)* 112:417-427.
- Johansen FF, Diemer NH. 1990. Temporal profile of interneuron and pyramidal cell protein synthesis in rat hippocampus following cerebral ischemia. *Acta Neuropathol* 81:14–19.
- Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust WJ, Gorno-Tempini ML, Schuff N. 2005. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. *Radiology* 234:851-859.
- Julio-Amilpas A, Montiel T, Soto-Tinoco E, Gerónimo-Olvera C, Massieu L. 2015. Protection of hypoglycemia-induced neuronal death by β -hydroxybutyrate involves the preservation of energy levels and decreased production of reactive oxygen species. *J Cereb Blood Flow Metab* 35:851-860.
- Kacimi R, Giffard RG, Yenari MA. 2011. Endotoxin-activated microglia injure brain derived endothelial cells via NF- κ B, JAK-STAT and JNK stress kinase pathways. *J Inflamm (Lond)* 8:7.
- Kadota T, Horinouchi T, Kuroda C. 2001. Development and aging of the cerebrum: assessment with proton MR spectroscopy. *AJNR Am J Neuroradiol* 22:128-135.
- Kalaria RN, Akinyemi R, Ihara M. 2012. Does vascular pathology contribute to Alzheimer changes? *J Neurol Sci* 322:141-147.
- Kalaria RN, Bhatti SU, Lust WD, Perry G. 1993. The amyloid precursor protein in ischemic brain injury and chronic hypoperfusion. *Ann N Y Acad Sci* 695:190-193.
- Kalaria RN. 2010. Vascular Basis for Brain Degeneration: Faltering Controls and Risk Factors for Dementia. *Nutr Rev* 68(Suppl 2): S74–S87.
- Kalogeropoulos A, Georgiopoulou V, Psaty BM, Rodondi N, Smith AL, Harrison DG, Liu Y, Hoffmann U, Bauer DC, Newman AB, Kritchevsky SB, Harris TB, Butler J. 2010. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. *J Am Coll Cardiol* 55:2129-2137.
- Kanekura K, Suzuki H, Aiso S, Matsuoka M. 2009. ER stress and unfolded protein response in amyotrophic lateral sclerosis. *Mol Neurobiol* 39:81–89.
- Kanoski SE, Davidson TL. 2011. Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity. *Physiol Behav* 103:59-68.
- Karlamangla AS, Miller-Martinez D, Lachman ME, Tun PA, Koretz BK, Seeman TE. 2014. Biological correlates of adult cognition: Midlife in the United States (MIDUS). *Neurobiol Aging* 35:395-407.
- Kennelly SP, Lawlor BA, Kenny RA. 2009. Blood pressure and the risk for dementia: a double-edged sword. *Ageing Res Rev* 8:61-70.
- Kent BD, Grote L, Ryan S, Pépin JL, Bonsignore MR, Tkacova R, Saaresranta T, Verbraecken J, Lévy P, Hedner J, McNicholas WT. 2014. Diabetes mellitus prevalence and control in sleep-disordered breathing: The European Sleep Apnea Cohort (ESADA) study. *Chest* 146:982–990.
- Kerber KA, Whitman GT, Brown DL, Baloh RW. 2006. Increased risk of death in community-dwelling older people with white matter hyperintensities on MRI. *J Neurol Sci* 250:33-38.
- Kerti L, Witte AV, Winkler A, Grittner U, Rujescu D, Floel A. 2013. Higher glucose levels associated with lower memory and reduced hippocampal microstructure. *Neurology* 81: 1746-1752.
- Kim HA, Miller AA, Drummond GR, Thrift AG, Arumugam TV, Phan TG, Srikanth VK, Sobey CG. 2012. Vascular cognitive impairment and Alzheimer's disease: role of cerebral hypoperfusion and oxidative stress. *Naunyn Schmiedeberg Arch Pharmacol* 385:953-959.
- Kim I, Xu W, Reed JC. 2008. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. *Nat Rev Drug Discov* 7:1013–1030.

- Kim WK. 1999. S-nitrosation ameliorates homocysteine-induced neurotoxicity and calcium responses in primary culture of rat cortical neurons. *Neurosci Lett* 265: 99–102.
- Kirino T. 1982. Delayed neuronal death in the gerbil hippocampus following ischemia. *Brain Res* 239:57–69.
- Kirino T, Sano K. 1984. Fine structural nature of delayed neuronal death following ischemia in the gerbil hippocampus. *Acta Neuropathol* 62:209–218.
- Kirino T, Tamura A, Sano K. 1984. Delayed neuronal death in rat hippocampus following transient forebrain ischemia. *Acta Neuropathol* 64:139–147.
- Kitagawa K, Matsumoto M, Niinobe M, Mikoshiba K, Hata R, Ueda H, Handa N, Fukunaga R, Isaka Y, Kimura K. 1989. Microtubule-associated protein 2 as a sensitive marker for cerebral ischemic damage. Immunohistochemical investigation of dendritic damage. *Neuroscience* 31:401–411.
- Kivipelto M., Ngandu T., Fratiglioni L., Viitanen M., Kareholt I., Winblad B. Helkala EL, Tuomilehto J, Soininen H, Nissinen A. 2005. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. *Arch Neurol* 62: 1556–1560.
- Kljajevic V, Grothe MJ, Ewers M, Teipel S. 2014. Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease. *Neurobiol Aging* 35:1973–1981.
- Knight EM, Martins IV, Gümüşgöz S, Allan SM, Lawrence CB. 2014. High-fat diet-induced memory impairment in triple-transgenic Alzheimer's disease (3xTgAD) mice is independent of changes in amyloid and tau pathology. *Neurobiol Aging* 35:1821–1832.
- Knopman DS, Jack CR Jr, Wiste HJ, Lundt ES, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Roberts RO, Boeve BF, Petersen RC. 2014. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. *Neurobiol Aging* 35:2096–2106.
- Knopman DS, Jack CR Jr, Lundt ES, Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Machulda MM, Roberts RO, Boeve BF, Jones DT, Petersen RC. 2015. Role of β -Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. *JAMA Neurol* 72:1475–1483.
- Koike MA, Garcia FG, Kitazawa M, Green KN, Laferla FM. 2011. Long term changes in phospho-APP and tau aggregation in the 3xTg-AD mice following cerebral ischemia. *Neurosci Lett* 495:55–59.
- Kolb AF, Petrie L. 2013. Folate deficiency enhances the inflammatory response of macrophages. *Mol Immunol* 54:164–172.
- Korani MS, Farbood Y, Sarkaki A, Fathi Moghaddam H, Taghi Mansouri M. 2014. Protective effects of gallic acid against chronic cerebral hypoperfusion-induced cognitive deficit and brain oxidative damage in rats. *Eur J Pharmacol* 733:62–67.
- Kovacic JC, Fuster V. 2012. Atherosclerotic risk factors, vascular cognitive impairment, and Alzheimer disease. *Mt Sinai J Med* 79:664–673.
- Kövari E, Gold G, Herrmann FR, Canuto A, Hof PR, Bouras C, Giannakopoulos P. 2007. Cortical microinfarcts and demyelination affect cognition in cases at high risk for dementia. *Neurology* 68:927–931.
- Kövari E, Gold G, Herrmann FR, Canuto A, Hof PR, Michel JP, Bouras C, Giannakopoulos P. 2004. Cortical microinfarcts and demyelination significantly affect cognition in brain aging. *Stroke* 35:410–414.
- Kramer PL, Xu H, Woltjer RL, Westaway SK, Clark D, Erten-Lyons D, Kaye JA, Welsh-Bohmer KA, Troncoso JC, Markesbery WR, Petersen RC, Turner RS, Kukull WA, Bennett DA, Galasko D, Morris JC, Ott J. 2011. Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study. *Neurobiol Aging* 32:2113–2122.
- Kreipke CW, Rafols JA, Reynolds CA, Schafer S, Marinica A, Bedford C, Fronczak M, Kuhn D, Armstead WM. Clazosentan, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain injury. *Neurol Res* 2011;33: 208–213.
- Krayer A, Soplop N, Strickland S, Norris EH. 2015. Chronic Hypertension Leads to Neurodegeneration in the TgSwDI Mouse Model of Alzheimer's disease. *Hypertension* 66:175–182.

- Kumagai T, Walberer M, Nakamura H, Endepols H, Sué M, Vollmar S, Adib S, Mies G, Yoshimine T, Schroeter M, Graf R. 2010. Distinct spatiotemporal patterns of spreading depolarizations during early infarct evolution: evidence from real-time imaging. *J Cereb Blood Flow Metab* 31: 580–592.
- Kwon KJ, Lee EJ, Kim MK, Kim SY, Kim JN, Kim JO, Kim HJ, Kim HY, Han JS, Shin CY, Han SH. 2015. Diabetes augments cognitive dysfunction in chronic cerebral hypoperfusion by increasing neuronal cell death: implication of cilostazol for diabetes mellitus-induced dementia. *Neurobiol Dis* 73:12–23.
- Lacalle-Aurioles M, Mateos-Pérez JM, Guzmán-De-Villoria JA, Olazarán J, Cruz-Orduña I, Alemán-Gómez Y, Martino ME, Desco M. 2014. Cerebral blood flow is an earlier indicator of perfusion abnormalities than cerebral blood volume in Alzheimer's disease. *J Cerebral Blood Flow Metab* 34, 654–659.
- Lafon-Cazal M, Pietri S, Culcasi M, Bockaert J. 1993. NMDA-dependent superoxide production and neurotoxicity. *Nature (London)* 364:535–537.
- Laiho KU, Shelburne JD, Trump BJ. 1971. Observations on cell volume, ultrastructure, mitochondrial conformation and vital-dye up-take in Ehrlich ascites tumor cells. *Am J Pathol* 65:203–230.
- Laiho KU, Trump BJ. 1975. Studies on the pathogenesis of cell injury. Effects of inhibitors of metabolism and membrane function on the mitochondria of Ehrlich ascites tumor cells. *Lab Invest* 32:163–182.
- Lashuel HA. 2005. Membrane permeabilization: a common mechanism in protein-misfolding diseases. *Sci Aging Knowl Environ*: pe28.
- Last D, Alsop DC, Abduljalil AM, Marquis RP, de Bazelaire C, Hu K, Cavallerano J, Novak V. 2007. Global and regional effects of type 2 diabetes on brain tissue volumes and cerebral vasoreactivity. *Diabetes Care* 30:1193–1199.
- Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ. 2000. Midlife blood pressure and dementia: the Honolulu-Asia aging study. *Neurobiol Aging* 21:49–55.
- Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, Strong AJ. 2011. Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. *J Cereb Blood Flow Metab* 31: 17–35.
- Lauritzen M. 1987. Regional cerebral blood flow during cortical spreading depression in rat brain: increased reactive hyperperfusion in low-flow states. *Acta Neurol Scand* 75: 1–8.
- Lecrux C, Hamel E. 2011. The neurovascular unit in brain function and disease. *Acta Physiol (Oxf)* 203:47–59.
- Lee JH, Park SY, Shin HK, Kim CD, Lee WS, Hong KW. 2008. Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury. *CNS Neurosci Ther* 14:143–152.
- Leenders KL, Perani D, Lammertsma AA, Heather JD, Buckingham P, Healy MJ, Gibbs JM, Wise RJ, Hatazawa J, Herold S, et al. 1990. Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. *Brain* 113:27–47.
- Lei S, Zhang P, Li W, Gao M, He X, Zheng J, Li X, Wang X, Wang N, Zhang J, Qi C, Lu H, Chen X, Liu Y. 2014. Pre- and posttreatment with edaravone protects CA1 hippocampus and enhances neurogenesis in the subgranular zone of dentate gyrus after transient global cerebral ischemia in rats. *ASN Neuro* 6: pii: 1759091414558417.
- Lin CM, Tseng YC, Hsu HL, Chen CJ, Chen DY, Yan FX, Chiu WT. 2016. Arterial Spin Labeling Perfusion Study in the Patients with Subacute Mild Traumatic Brain Injury. *PLoS One* 11:e0149109.
- Lindholm D, Wootz H, Korhonen L. 2006. ER stress and neurodegenerative diseases. *Cell Death Differ* 13:385–392.
- Lipton SA, Rosenberg PA. 1994. Excitatory amino acids as a final common pathway for neurologic disorders. *N Engl J Med* 330:613–622.
- Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, Arnelle DR, Stamler JS. 1997. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. *Proc Natl Acad Sci U S A* 94:5923–5928.
- Liu H, Zhang J. 2012. Cerebral hypoperfusion and cognitive impairment: the pathogenic role of vascular oxidative stress. *Int J Neurosci* 122:494–499.

- Liu J., Xu Y., Zhang H., Gao X., Fan H., Wang G. 2014. Coronary flow velocity reserve is impaired in hypertensive patients with hyperhomocysteinemia. *J. Human Hypertens* 28: 743–747.
- Liu X, Wang Z, Wang P, Yu B, Liu Y, Xue Y. 2013. Green tea polyphenols alleviate early BBB damage during experimental focal cerebral ischemia through regulating tight junctions and PKC α signaling. *BMC Complement Altern Med* 13:187.
- Logue J, Walker JJ, Colhoun HM, Leese GP, Lindsay RS, McKnight JA, Morris AD, Pearson DW, Petrie JR, Philip S, Wild SH, Sattar N. 2011. Do men develop type 2 diabetes at lower body mass indices than women? *Diabetologia* 54:3003-3006.
- Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. 1999. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. *Am J Pathol* 155:853–862.
- MacManus JP, Hill IE, Preston E, Rasquinha I, Walker T, Buchan AM. 1995. Differences in DNA fragmentation following transient cerebral ischemia or decapitation ischemia in rats. *J Cereb Blood Flow Metab* 15:728–737.
- Madsen SK, Rajagopalan P, Joshi SH, Toga AW, Thompson PM. 2015. Higher homocysteine associated with thinner cortical gray matter in 803 participants from the Alzheimer's Disease Neuroimaging Initiative. *Neurobiol Aging* 36 Suppl 1:S203-S210.
- Magistretti PJ, Pellerin L. 1999. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. *Philos Trans R Soc Lond B Biol Sci* 354:1155-1163.
- Magnotta VA, Andreasen NC, Schultz SK, Harris G, Cizadlo T, Heckel D, Nopoulos P, Flaum M. 1999. Quantitative in vivo measurement of gyrification in the human brain: changes associated with aging. *Cereb Cortex* 9:151-160.
- Mansouri MT, Farbood Y, Sameri MJ, Sarkaki A, Naghizadeh B, Rafeirad M. 2013. Neuroprotective effects of oral gallic acid against oxidative stress induced by 6-hydroxydopamine in rats. *Food Chem* 138:1028-1033.
- Marchant NL, Reed BR, Sanossian N, Madison CM, Kriger S, Dhada R, Mack WJ, DeCarli C, Weiner MW, Mungas DM, Chui HC, Jagust WJ. 2013. The aging brain and cognition: contribution of vascular injury and $\alpha\beta$ to mild cognitive dysfunction. *JAMA Neurol* 70:488-495.
- Martin LJ, Brambrink AM, Lehmann C, Portera-Cailliau C, Koehler R, Rothstein J, Traystman RJ. 1997a. Hypoxia-ischemia causes abnormalities in glutamate transporters and death of astroglia and neurons in newborn striatum. *Ann Neurol* 42:335–348.
- Martin LJ, Brambrink A, Koehler RC, Traystman RJ. 1997b. Primary sensory and forebrain motor systems in the newborn brain are preferentially damaged by hypoxia-ischemia. *J Comp Neurol* 377:262–285.
- Martin LJ, Al-Abdulla NA, Brambrink AM, Kirsch JR, Sieber FE, Portera-Cailliau C. 1998. Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: a perspective on the contributions of apoptosis and necrosis. *Brain Res Bull* 46:281–309.
- Martin LJ, Sieber FE, Traystman RJ. 2000. Apoptosis and Necrosis Occur in Separate Neuronal Populations in Hippocampus and Cerebellum after Ischemia and Are Associated With Differential Alterations in Metabotropic Glutamate Receptor Signaling Pathways. *J Cereb Blood Flow Metab* 20:153-167.
- Massie BM. 2002. Obesity and heart failure—risk factor or mechanism? *N Engl J Med* 347: 358–359.
- Matsumoto T, Noguchi E, Ishida K, Nakayama N, Kobayashi T, Kamata K. 2008. Cilostazol improves endothelial dysfunction by increasing endothelium-derived hyperpolarizing factor response in mesenteric arteries from Type 2 diabetic rats. *Eur J Pharmacol* 599:102-109.
- Mattsson N, Tosun D, Insel PS, Simonson A, Jack CR Jr, Beckett LA, Donohue M, Jagust W, Schuff N, Weiner MW. 2014. Association of brain amyloid- β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. *Brain* 137:1550-1561.
- Matus S, Lisbona F, Torres M, Leon C, Thielen P, Hetz C. 2008. The stress rheostat: an interplay between the unfolded protein response (UPR) and autophagy in neurodegeneration. *Curr Mol Med* 8:157–172.

- Meguro K, Blaizot X, Kondoh Y, Le Mestric C, Baron JC, Chavoix C. 1999. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. *Brain* 122:1519-1531.
- Mehrabian S, Duron E, Labouree F, Rollot F, Bune A, Traykov L, Hanon O. 2010. Relationship between orthostatic hypotension and cognitive impairment in the elderly. *J Neurol Sci* 299:45-48.
- Michael BD, Griffiths MJ, Granerod J, Brown D, Keir G, Wnęk M, Cox DJ, Vidyasagar R, Borrow R, Parkes LM, Solomon T. 2016. The interleukin-1 balance is associated with clinical severity, blood-brain barrier permeability, neuroimaging changes and outcome in encephalitis. *J Infect Dis* 213:1651-1660.
- Millien I, Blaizot X, Giffard C, Mezenge F, Insausti R, Baron JC, Chavoix C. 2002. Brain glucose hypometabolism after perirhinal lesions in baboons: implications for Alzheimer disease and aging. *J Cereb Blood Flow Metab* 22:1248-1261.
- Misiak B, Leszek J, Kiejna A. 2012. Metabolic syndrome, mild cognitive impairment and Alzheimer's disease--the emerging role of systemic low-grade inflammation and adiposity. *Brain Res Bull* 89:144-149.
- Miyamoto N, Tanaka R, Zhang N, Shimura H, Onodera M, Mochizuki H, Hattori N, Urabe T. 2009. Crucial role for Ser133-phosphorylated form of cyclic AMP-responsive element binding protein signaling in the differentiation and survival of neural progenitors under chronic cerebral hypoperfusion. *Neuroscience* 162:525-536.
- Moroz LL, Kohn AB. 2010. Do different neurons age differently? Direct genome-wide analysis of aging in single identified cholinergic neurons. *Front Aging Neurosci* 2: pii: 6.
- Morrell MJ, Finn L, Kim H, Peppard PE, Badr MS, Young T. 2000. Sleep fragmentation, awake blood pressure, and sleep-disordered breathing in a population-based study. *Am J Respir Crit Care Med* 162:2091-2096.
- Morrell MJ, Jackson ML, Twigg GL, Ghiassi R, McRobbie DW, Quest RA, Pardoe H, Pell GS, Abbott DF, Rochford PD, Jackson GD, Pierce RJ, O'Donoghue FJ, Corfield DR. 2010. Changes in brain morphology in patients with obstructive sleep apnoea. *Thorax* 65:908-914.
- Mortby ME, Janke AL, Anstey KJ, Sachdev PS, Cherbuin N. 2013. High 'normal' blood glucose is associated with decreased brain volume and cognitive performance in the 60s: the PATH through life study. *PLoS One* 8: e73697.
- Mormino EC, Betensky RA, Hedden T, Schultz AP, Amariglio RE, Rentz DM, Johnson KA, Sperling RA. 2014. Synergistic Effect of β -Amyloid and Neurodegeneration on Cognitive Decline in Clinically Normal Individuals. *JAMA Neurol* 71:1379-1385.
- Mosconi L, Pupi A, De Cristofaro MT, Fayyaz M, Sorbi S, Herholz K. 2004. Functional interactions of the entorhinal cortex: an 18F-FDG PET study on normal aging and Alzheimer's disease. *J Nucl Med* 45:382-392.
- Mosconi L, Sorbi S, de Leon MJ, Li Y, Nacmias B, Myoung PS, Tsui W, Ginestroni A, Bessi V, Fayyazz M, Caffarra P, Pupi A. 2006. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. *J Nucl Med* 47:1778-1786.
- Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M, Laska E, Rusinek H, de Leon MJ. 2008. Hippocampal hypometabolism predicts cognitive decline from normal aging. *Neurobiol Aging* 29:676-692.
- Mrak RE. 2009. Alzheimer-type neuropathological changes in morbidly obese elderly individuals. *Clin Neuropathol* 28:40-45.
- Murray IV, Proza JF, Sohrabji F, Lawler JM. 2011. Vascular and metabolic dysfunction in Alzheimer's disease: a review. *Exp Biol Med* (Maywood) 236:772-82. 16.
- Nagafusa Y., Okamoto N., Sakamoto K., Yamashita F., Kawaguchi A., Higuchi, T., Matsuda H. 2012. Assessment of cerebral blood flow findings using 99mTc-ECD single-photon emission computed tomography in patients diagnosed with major depressive disorder. *J Affect Disord* 140: 296-299.
- Narayan S.K., Firkbank M.J., Saxby B.K., Stansby G., Hansrani M., O'Brien J.T., Ford GA. 2011. Elevated plasma homocysteine is associated with increased brain atrophy rates in older subjects with mild hypertension. *Dement Geriatr Cogn Disord* 31: 341-348.
- Nathoo N, Jalal H, Natah SS, Zhang Q, Wu Y, Dunn JF. 2016. Hypoxia and Inflammation-Induced

Disruptions of the Blood-Brain and Blood-Cerebrospinal Fluid Barriers Assessed Using a Novel T1-Based MRI Method. *Acta Neurochir Suppl* 121:23-28.

- Ni J, Ohta H, Matsumoto K, Watanabe H. 1994. Progressive cognitive impairment following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries in rats. *Brain Res* 653:231-236.
- Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D'Agostino RB, Newman AB, Lebowitz MD, Pickering TG. 2000. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. *JAMA* 283:1829-1836.
- Noda A, Ohba H, Kakiuchi T, Futatsubashi M, Tsukada H, Nishimura S. 2002. Age-related changes in cerebral blood flow and glucose metabolism in conscious rhesus monkeys. *Brain Res* 936: 76-81.
- Noor JI, Ikeda T, Mishima K, Aoo N, Ohta S, Egashira N, Iwasaki K, Fujiwara M, Ikenoue T. 2005. Short-term administration of a new free radical scavenger, edaravone, is more effective than its long-term administration for the treatment of neonatal hypoxic-ischemic encephalopathy. *Stroke* 36:2468-2474.
- Novak V, Last D, Alsop DC, Abduljalil AM, Hu K, Lepicovsky L, Cavallerano J, Lipsitz LA. 2006. Cerebral blood flow velocity and periventricular white matter hyperintensities in type 2 diabetes. *Diabetes Care* 29:1529-1534.
- Novati A, Hulshof HJ, Koolhaas JM, Lucassen PJ, Meerlo P. 2011. Chronic sleep restriction causes a decrease in hippocampal volume in adolescent rats, which is not explained by changes in glucocorticoid levels or neurogenesis. *Neuroscience* 190:145-155.
- O'Brien JT, Egger S, Syed GMS, Sahakian BJ, Levy R. 1992. A study of regional cerebral blood flow and cognitive performance in Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 55:1182-1187.
- Oh H, Habeck C, Madison C, Jagust W. 2014. Covarying alterations in A β deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. *Hum Brain Mapp* 35:297-308.
- Oh H, Madison C, Villeneuve S, Markley C, Jagust WJ. 2014. Association of gray matter atrophy with age, β -amyloid, and cognition in aging. *Cereb Cortex* 24:1609-1618.
- Okamoto Y, Yamamoto T, Kalara RN, Senzaki H, Maki T, Hase Y, Kitamura A, Washida K, Yamada M, Ito H, Tomimoto H, Takahashi R, Ihara M. 2012. Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. *Acta Neuropathol* 123:381-394.
- Okonkwo OC, Xu G, Oh JM, Dowling NM, Carlsson CM, Gallagher CL. 2014. Cerebral Blood Flow is Diminished in Asymptomatic Middle-Aged Adults with Maternal History of Alzheimer's Disease. *Cereb Cortex* 24:978-988.
- Olesen J, Larsen B, Lauritzen M. 1981. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. *Ann Neurol* 9:344-352.
- Ongali B, Nicolakakis N, Lecrux C, Aboulkassim T, Rosa-Neto P, Papadopoulos P, Tong XK, Hamel E. 2010. Transgenic mice overexpressing APP and transforming growth factor-beta1 feature cognitive and vascular hallmarks of Alzheimer's disease. *Am J Pathol* 177:3071-3080.
- Osmond JM, Mintz JD, Dalton B, Stepp DW. 2009. Obesity increases blood pressure, cerebral vascular remodeling, and severity of stroke in the Zucker rat. *Hypertension* 53:381-386.
- Ossenkoppele R, Schonhaut DR, Baker SL, O'Neil JP, Janabi M, Ghosh PM, Santos M, Miller ZA, Bettcher BM, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD. 2015. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. *Ann Neurol* 77:338-342.
- Ota M, Noda T, Sato N, Hattori K, Teraishi T, Hori H, Nagashima A, Shimoji K, Higuchi T, Kunugi H. 2014. Characteristic distributions of regional cerebral blood flow changes in major depressive disorder patients: a pseudo-continuous arterial spin labeling (pCASL) study. *J Affect Disord* 165:59-63.
- Pamidi S, Tasali E. 2012. Obstructive sleep apnea and type 2 diabetes: is there a link? *Front Neurol* 3:126.
- Panickar KS, Jang S. 2013. Dietary and plant polyphenols exert neuroprotective effects and improve cognitive function in cerebral ischemia. *Recent Pat Food Nutr Agric* 5:128-143.

- Pannacciulli N, Del Parigi A, Chen K, Le DS, Reiman EM, Tataranni PA. 2006. Brain abnormalities in human obesity: a voxel-based morphometric study. *Neuroimage* 31: 1419–1425.
- Pantano P, Baron JC, Lebrun-Grandie P, Duquesnoy N, Bousser MG, Comar D. 1984. Regional cerebral blood flow and oxygen consumption in human aging. *Stroke* 15:635-641.
- Papadopoulos P, Tong XK, Hamel E. 2014. Selective benefits of simvastatin in bitransgenic APPSwe,Ind/TGF- β 1 mice. *Neurobiol Aging* 35:203-212.
- Pardini M, Serrati C, Guida S, Mattei C, Abate L, Massucco D, Sassos D, Amore M, Krueger F, Cocito L, Emberti Gialloreti L. 2015. Souvenaid reduces behavioral deficits and improves social cognition skills in frontotemporal dementia: a proof-of-concept study. *Neurodegener Dis* 15:58-62.
- Parkin MC, Hopwood SE, Jones DA, Hashemi P, Landolt H, Fabricius M, Lauritzen M, Boutelle MG, Strong AJ. 2005. Dynamic changes in brain glucose and lactate in pericontusional areas of the human cerebral cortex, monitored with rapid sampling on-line microdialysis: relationship with depolarisation-like events. *J Cereb Blood Flow Metab* 25:402–413.
- Paschen W, Mengesdorf T. 2005. Cellular abnormalities linked to endoplasmic reticulum dysfunction in cerebrovascular disease - therapeutic potential. *Pharmacol Ther* 108:362–375.
- Peila R, White LR, Petrovich H, Masaki K, Ross GW, Havlik RJ, Launer LJ. 2001. Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia aging study. *Stroke* 32:2882-2889.
- Peppard PE, Young T, Palta M, Skatrud J. 2000. Prospective study of the association between sleep-disordered breathing and hypertension. *N Engl J Med* 342:1378–1384.
- Périco CA, Skaf CR, Yamada A, Duran F, Buchpiguel CA, Castro CC, Soares JC, Busatto GF. 2005. Relationship between regional cerebral blood flow and separate symptom clusters of major depression: a single photon emission computed tomography study using statistical parametric mapping. *Neurosci Lett* 384:265-270.
- Persidsky Y, Ramirez S, Haorah J, Kanmogne G. 2006. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. *J. Neuroimmune Pharmacol* 1:223–236.
- Petrea RE, Beiser A, Seshadri S, Kelly-Hayes M, Kase CS, Wolf PA. 2009. Gender differences in stroke incidence and poststroke disability in the Framingham Heart Study. *Stroke* 40:1032-1037.
- Petrovich H, White LR, Izmirlian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ. 2000. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. *Neurobiol Aging* 21:57-62.
- Pfefferbaum A, Adalsteinsson E, Sullivan EV. 2006. Dysmorphology and microstructural degradation of the corpus callosum: Interaction of age and alcoholism. *Neurobiol Aging* 27:994-1009.
- Pielerhoff P, Südmeyer M, Hömke L, Zilles K, Schnitzler A, Amunts K. 2008. Detection of structural changes of the human brain in longitudinally acquired MR images by deformation field morphometry: methodological analysis, validation and application. *Neuroimage* 43:269-287.
- Piert M, Koeppe RA, Giordani B, Berent S, Kuhl DE. 1996. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. *J Nucl Med* 37:201-208.
- Piilgaard H, Lauritzen M. 2009. Persistent increase in oxygen consumption and impaired neurovascular coupling after spreading depression in rat neocortex. *J Cereb Blood Flow Metab* 29: 1517–1527.
- Portera-Cailliau C, Price DL, Martin LJ. 1997a. Excitotoxic neuronal death in the immature brain is an apoptosis-necrosis morphological continuum. *J Comp Neurol* 378:70–87.
- Portera-Cailliau C, Price DL, Martin LJ. 1997b. Non-NMDA and NMDA receptor-mediated excitotoxic neuronal deaths in adult brain are morphologically distinct: further evidence for an apoptosis-necrosis continuum. *J Comp Neurol* 378:88–104.
- Powers WJ, Videen TO, J Markham J, Walter V, Perlmutter JS. 2011. Metabolic control of resting hemispheric cerebral blood flow is oxidative, not glycolytic. *J Cereb Blood Flow Metab* 31: 1223–1228.
- Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE. 2004. Sleep Heart Health Study

- Investigators. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. *Am J Epidemiol*. 160:521–530.
- Qiu C, Winblad B, Fratiglioni L. 2005. The age-dependent relation of blood pressure to cognitive function and dementia. *Lancet Neurol* 4:487–499.
- Qu J, Zhou Q, Du Y, Zhang W, Bai M, Zhang Z, Xi Y, Li Z, Miao J. 2014. Rutin protects against cognitive deficits and brain damage in rats with chronic cerebral hypoperfusion. *Br J Pharmacol* 171:3702–3715.
- Raji CA, Lopez OL, Kuller LH, Carmichael OT, Becker JT. 2009. Age, Alzheimer disease, and brain structure. *Neurology* 73:1899–1905.
- Raji CA, Ho AJ, Parikshak NN, Becker JT, Lopez OL, Kuller LH, Hua X, Leow AD, Toga AW, Thompson PM. 2010. Brain structure and obesity. *Hum Brain Mapp* 31:353–364.
- Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. 2004. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. *Proc Natl Acad Sci U S A* 101:284–289.
- Revesz T, Holton JL, Lashley T, Plant G, Rostagno A, Ghiso J, Frangione B. 2002. Sporadic and familial cerebral amyloid angiopathies. *Brain Pathol* 12:343–357.
- Richieri R, Boyer L, Faget-Agius C, Farisse J, Mundler O, Lançon C, Guedj E. 2015. Determinants of brain SPECT perfusion and connectivity in treatment-resistant depression. *Psychiatry Res* 231:134–140.
- Ritchie CW, Bajwa J, Coleman G, Hope K, Jones RW, Lawton M, Marven M, Passmore P. 2014. Souvenaid®: a new approach to management of early Alzheimer's disease. *J Nutr Health Aging* 18:291–299.
- Riudavets MA, Iacono D, Resnick SM, O'Brien R, Zonderman AB, Martin LJ, Rudow G, Pletnikova O, Troncoso JC. 2007. Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons. *Neurobiol Aging* 28:1484–1492.
- Rius-Pérez S, Tormos AM, Pérez S, Taléns-Visconti R. 2015. Vascular pathology: Cause or effect in Alzheimer disease? *Neurologia* 2015 Sep 15. pii: S0213-4853(15)00185-1. doi: 10.1016/j.nrl.2015.07.010. [Epub ahead of print].
- Rocchi A, Orsucci D, Tognoni G, Ceravolo R, Siciliano G. 2009. The role of vascular factors in late-onset sporadic Alzheimer's disease. Genetic and molecular aspects. *Curr Alzheimer Res* 6:224–237.
- Rodrigue KM. 2013. Contribution of cerebrovascular health to the diagnosis of Alzheimer disease. *JAMA Neurol* 70:438–439.
- Romero K, Black SE, Feinstein A. 2014. Differences in cerebral perfusion deficits in mild traumatic brain injury and depression using single-photon emission computed tomography. *Front Neurol* 5:158.
- Ron D, Walter P. 2007. Signal integration in the endoplasmic reticulum unfolded protein response. *Nat Rev Mol Cell Biol* 8:519–529.
- Rosenberg GA. 2009. Inflammation and white matter damage in vascular cognitive impairment. *Stroke* 40:S20–S23.
- Rosvall L, Rizzuto D, Wang HX, Winblad B, Graff C, Fratiglioni L. 2009. APOE-related mortality: effect of dementia, cardiovascular disease and gender. *Neurobiol Aging* 30:1545–1551.
- Sachdev P, Parslow R, Salonikas C, Lux O, Wen W, Kumar R, Naidoo D, Christensen H, Jorm A. 2004. Homocysteine and the brain in midadult life: evidence for an increased risk of leukoaraiosis in men. *Arch Neurol* 61:1369–1376.
- Sagare AP, Bell RD, Zlokovic BV. 2013. Neurovascular defects and faulty amyloid- β vascular clearance in Alzheimer's disease. *J Alzheimers Dis* 33:S87–100.
- Salat DH, Buckner RL, Snyder AZ, Greve DN, Desikan RS, Busa E, Morris JC, Dale AM, Fischl B. 2004. Thinning of the cerebral cortex in aging. *Cereb Cortex* 14:721–730.
- Salat DH, Tuch DS, Greve DN, van der Kouwe AJ, Hevelone ND, Zaleta AK, Rosen BR, Fischl B, Corkin

- S, Rosas HD, Dale AM. 2005. Age-related alterations in white matter microstructure measured by diffusion tensor imaging. *Neurobiol Aging* 26:1215-1227.
- Salminen A, Kauppinen A, Suuronen T, Kaarniranta K, Ojala J. 2009. ER stress in Alzheimer's disease: a novel neuronal trigger for inflammation and Alzheimer's pathology. *J Neuroinflammation* 6:41.
- Sambati L, Calandra-Buonaura G, Poda R, Guaraldi P, Cortelli P. 2014. Orthostatic hypotension and cognitive impairment: a dangerous association? *Neurol Sci* 35:951-957.
- Samuraki M, Matsunari I, Yoshita M, Shima K, Noguchi-Shinohara M, Hamaguchi T, Ono K, Yamada M. 2015. Cerebral Amyloid Angiopathy-Related Microbleeds Correlate with Glucose Metabolism and Brain Volume in Alzheimer's Disease. *J Alzheimers Dis* 48:517-528.
- Sarti C, Pantoni L, Bartolini L, Inzitari D. 2002. Cognitive impairment and chronic cerebral hypoperfusion: what can be learned from experimental models. *J Neurol Sci* 203-204:263-266.
- Scheckenbach KEL, Dreier JP, Dirnagl U, Lindauer U. 2006. Impaired cerebrovascular reactivity after cortical spreading depression in rats: restoration by nitric oxide or cGMP. *Exp Neurol* 202:449-455.
- Scheper W, Hoozemans JJ. 2009. Endoplasmic reticulum protein quality control in neurodegenerative disease: the good, the bad and the therapy. *Curr Med Chem* 16:615-626.
- Schliebs R, Arendt T. 2011. The cholinergic system in aging and neuronal degeneration. *Behav Brain Res* 221:555-563.
- Schroder M, Kaufman RJ. 2005. The mammalian unfolded protein response. *Annu Rev Biochem* 74:739-789.
- Bernales S, Papa FR, Walter P. 2006. Intracellular signaling by the unfolded protein response. *Annu Rev Cell Dev Biol* 22:487-508.
- Schubert GA, Schilling L, Thomé C. 2008. Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats. *J Neurosurg* 109:1134-1140.
- Schwarz S, Zhou GZ, Katki AG, Rodbard D. 1990. L-homocysteate stimulates [3H]MK-801 binding to the phencyclidine recognition site and is thus an agonist for the N-methyl-D-aspartate-operated cation channel. *Neuroscience* 37:193-200.
- Scioli MG, Bielli A, Agostinelli S, Tarquini C, Arcuri G, Ferlosio A, Costanza G, Doldo E, Orlandi A. 2014. Antioxidant treatment prevents serum deprivation- and TNF- α -induced endothelial dysfunction through the inhibition of NADPH oxidase 4 and the restoration of β -oxidation. *J Vasc Res* 51:327-337.
- Seo SW, Cho SS, Park A, Chin J, Na DL. 2009. Subcortical vascular versus amnesic mild cognitive impairment: comparison of cerebral glucose metabolism. *J Neuroimaging* 19:213-219.
- Shah NS, Vidal JS, Masaki K, Petrovitch H, Ross GW, Tilley C, DeMattos RB, Tracy RP, White LR, Launer LJ. 2012. Midlife blood pressure, plasma β -amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. *Hypertension* 59:780-786.
- Shen J, Wu J. 2015. Nicotinic Cholinergic Mechanisms in Alzheimer's Disease. *Int Rev Neurobiol* 124:275-292.
- Shen L, Ji HF. 2015. Associations between Homocysteine, Folic Acid, Vitamin B12 and Alzheimer's Disease: Insights from Meta-Analyses. *J Alzheimers Dis* 46:777-790.
- Shin HK, Dunn AK, Jones PB, Boas DA, Moskowitz MA, Ayata C. 2006. Vasoconstrictive neurovascular coupling during focal ischemic depolarizations. *J Cereb Blood Flow Metab* 26: 1018-1030.
- Shiran A, Remer E, Asmer I, Karkabi B, Zittan E, Cassel A, Barak M, Rozenberg O, Karkabi K, Flugelman MY. 2015. Association of Vitamin B12 Deficiency with Homozygosity of the TT MTHFR C677T Genotype, Hyperhomocysteinemia, and Endothelial Cell Dysfunction. *Isr Med Assoc J* 17:288-292.
- Simionescu M, Antohe F. 2006. Functional ultrastructure of the vascular endothelium: changes in various pathologies. *Handb. Exp Pharmacol* 176:41-69.
- Simon RP, Swan JH, Griffiths T, Meldrum BS. 1984. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. *Science* 226:850-852.

- Simmons NE, H.M. Do HM, Lipper MH, Laws Jr. ER. 2000. Cerebral atrophy in Cushing's disease, Surg Neurol 53:72–76.
- Skoog I, Gustafson D. 2003. Hypertension, hypertension-clustering factors and Alzheimer's disease. Neurol Res 25:675–680.
- Skoog I, Gustafson D. 2006. Update on hypertension and Alzheimer's disease. Neurol Res 28:605–611.
- Solfrizzi V, Scafato E, Capurso C, D'Introno A, Colacicco AM, Frisardi V, Vendemiale G, Baldereschi M, Crepaldi G, Di Carlo A, Galluzzo L, Gandin C, Inzitari D, Maggi S, Capurso A, Panza F. 2011. Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal Study on Aging. Neurobiol Aging 32:1932–1941.
- Sowell ER, Peterson BS, Thompson PM, Welcome SE, Henkenius AL, Toga AW. 2003. Mapping cortical change across the human life span. Nat Neurosci 6:309–315.
- Stamler J S, Osborne J A, Jaraki O, Rabbani L E, Mullins M, Singel D, Loscalzo J. 1993. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91:308–318.
- Stein DM, Lindell A, Murdock KR, Kufera JA, Menaker J, Keledjian K, Bochicchio GV, Aarabi B, Scalea TM. 2011. Relationship of serum and cerebrospinal fluid biomarkers with intracranial hypertension and cerebral hypoperfusion after severe traumatic brain injury. J Trauma 70:1096–1103.
- Stocker RP, Cieply MA, Paul B, Khan H, Henry L, Kontos AP, Germain A. 2014. Combat-related blast exposure and traumatic brain injury influence brain glucose metabolism during REM sleep in military veterans. Neuroimage 99:207–214.
- Strong AJ, Anderson PJ, Watts HR, Virley DJ, Lloyd A, Irving EA, Nagafuji T, Ninomiya M, Nakamura H, Dunn AK, Graf R. 2007. Peri-infarct depolarizations lead to loss of perfusion in ischaemic gyrencephalic cerebral cortex. Brain 130: 995–1008.
- Stulemeijer M., Vos PE., van der Werf S., van Dijk G., Rijpkema M., Fernandez G. 2010. How mild traumatic brain injury may affect declarative memory performance in the post-acute stage. J Neurotrauma 27:1585–1595.
- Su JH, Cummings BJ, Cotman CW. 1996. Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments. Brain Res 739:79–87.
- Sudduth TL, Powell DK, Smith CD, Greenstein A, Wilcock DM. 2013. Induction of hyperhomocysteinemia models vascular dementia by induction of cerebral microhemorrhages and neuroinflammation. J Cereb Blood Flow Metab 33:708–715.
- Sun YY, Li Y, Wali B, Li Y, Lee J, Heinmiller A, Abe K, Stein DG, Mao H, Sayeed I, Kuan CY. 2015. Prophylactic Edaravone Prevents Transient Hypoxic-Ischemic Brain Injury: Implications for Perioperative Neuroprotection. Stroke 46:1947–1955.
- Sutton ET, Thomas T, Bryant MW, Landon CS, Newton CA, Rhodin JA. 1999. Amyloid-beta peptide induced inflammatory reaction is mediated by the cytokines tumor necrosis factor and interleukin-1. J Submicrosc Cytol Pathol 31:313–323.
- Takada H, Nagata K, Hirata Y, Satoh Y, Watahiki Y, Sugawara J, Yokoyama E, Kondoh Y, Shishido F, Inugami A. 1992. Age-related decline of cerebral oxygen metabolism in normal population detected with positron emission tomography. Neurol Res 14:128–131.
- Takayama N, Iseki E, Yamamoto T, Kosaka K. 2002. Regional quantitative study of formation process of neurofibrillary tangles in the hippocampus of non-demented elderly brains: comparison with late-onset Alzheimer's disease brains. Neuropathology 22:147–153.
- Takeda S, Sato N, Ogihara T, Morishita R. 2008. The renin-angiotensin system, hypertension and cognitive dysfunction in Alzheimer's disease: new therapeutic potential. Front Biosci 13:2253–2265.
- Taki Y, Kinomura S, Sato K, Goto R, Kawashima R, Fukuda H. 2011. A longitudinal study of gray matter volume decline with age and modifying factors. Neurobiol Aging 32:907–915.
- Taniguchi M, Uchinami M, Doi K, Yoshida M, Sasaki H, Tamagawa K, Horiuchi T, Tanaka K. 2007. Edaravone reduces ischemia-reperfusion injury mediators in rat liver. J Surg Res 137:69–74.

- Tarczyluk MA, Nagel DA, Rhein Parri H, Tse EH, Brown JE, Coleman MD, Hill EJ. 2015. Amyloid β 1-42 induces hypometabolism in human stem cell-derived neuron and astrocyte networks. *J Cereb Blood Flow Metab* 35:1348-1357.
- Tchistiakova E, Anderson ND, Greenwood CE, MacIntosh BJ. 2014. Combined effects of type 2 diabetes and hypertension associated with cortical thinning and impaired cerebrovascular reactivity relative to hypertension alone in older adults. *Neuroimage Clin* 5:36-41.
- ten Dam VH, van den Heuvel DM, de Craen AJ, Bollen EL, Murray HM, Westendorp RG, Blauw GJ, van Buchem MA. 2007. Decline in total cerebral blood flow is linked with increase in periventricular but not deep white matter hyperintensities. *Radiology* 243:198-203.
- Thal DR, Capetillo-Zarate E, Larionov S, Staufenbiel M, Zurbuegg S, Beckmann N. 2009. Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. *Neurobiol Aging* 30: 1936-1948.
- Thilmann R, Xie Y, Kleihues P, Kiessling M. 1986. Persistent inhibition of protein synthesis precedes delayed neuronal death in postischemic gerbil hippocampus. *Acta Neuropathol* 71:88-93.
- Thomas T, Sutton ET, Bryant MW, Rhodin JA. 1997. In vivo vascular damage, leukocyte activation and inflammatory response induced by beta-amyloid. *J Submicrosc Cytol Pathol* 29:293-304.
- Toda N, Ayajiki K, Okamura T. 2014. Obesity-induced cerebral hypoperfusion derived from endothelial dysfunction: one of the risk factors for Alzheimer's disease. *Curr Alzheimer Res* 11:733-744.
- Tomassoni D, Nwankwo IE, Gabrielli MG, Bhatt S, Muhammad AB, Lokhandwala MF, Tayebati SK, Amenta F. 2013. Astroglialosis in the brain of obese Zucker rat: a model of metabolic syndrome. *Neurosci Lett* 543:136-141.
- Tong XK, Hamel E. 2015. Simvastatin restored vascular reactivity, endothelial function and reduced string vessel pathology in a mouse model of cerebrovascular disease. *J Cereb Blood Flow Metab* 35:512-520.
- Troen AM, Shea-Budgell M, Shukitt-Hale B, Smith DE, Selhub J, Rosenberg IH. 2008. B-vitamin deficiency causes hyperhomocysteinemia and vascular cognitive impairment in mice. *Proc Natl Acad Sci USA* 105:12474-1249.
- Truelove D, Shuaib A, Ijaz S, Richardson S, Kalra J. 1994. Superoxide dismutase, catalase, and U78517F attenuate neuronal damage in gerbils with repeated brief ischemic insults. *Neurochem Res* 19:665-671.
- Uemura K, Shimada H, Doi T, Makizako H, Park H, Suzuki T. 2014. Depressive symptoms in older adults are associated with decreased cerebral oxygenation of the prefrontal cortex during a trail-making test. *Arch Gerontol Geriatr* 59:422-428.
- Ueno Y, Koike M, Shimada Y, Shimura H, Hira K, Tanaka R, Uchiyama Y5, Hattori N3, Urabe T. 2015. L-carnitine enhances axonal plasticity and improves white-matter lesions after chronic hypoperfusion in rat brain. *J Cereb Blood Flow Metab* 35:382-91.
- Ueno Y, Zhang N, Miyamoto N, Tanaka R, Hattori N, Urabe T. 2009. Edaravone attenuates white matter lesions through endothelial protection in a rat chronic hypoperfusion model. *Neuroscience* 162:317-327.
- Ullrich C, Pirchl M, Humpel C. 2010. Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. *Mol Cell Neurosci* 45:408-417.
- Urbano F, Roux F, Schindler J, Mohsenin V. 2008. Impaired cerebral autoregulation in obstructive sleep apnea. *J Appl Physiol* (1985) 105:1852-1857.
- Valenti R, Pantoni L, Markus HS. 2014. Treatment of vascular risk factors in patients with a diagnosis of Alzheimer's disease: a systematic review. *BMC Med* 12:160.
- Van Der Gucht A, Verger A, Yagdigul Y, Poussier S, Joly L, Watfa G, Benetos A, Karcher G, Marie PY. 2015. Complementarity of visual and voxel-based FDG-PET analysis to detect MCI-like hypometabolic pattern in elderly patients with hypertension and isolated memory complaints. *Acta Radiol* 56:980-989.

- Van Putten HP, Bouwhuis MG, Muizelaar JP, Lyeth BG, Berman RF. 2005. Diffusion-weighted imaging of edema following traumatic brain injury in rats: effects of secondary hypoxia. *J Neurotrauma* 22:857-872.
- Vanzetta I, Grinvald A. 2008. Coupling between neuronal activity and microcirculation: implications for functional brain imaging. *HFSP J* 2: 79–98.
- Vasic N, Wolf ND, Grön G, Sosic-Vasic Z, Connemann BJ, Sambataro F, von Strombeck A, Lang D, Otte S, Dudek M, Wolf RC. 2015. Baseline brain perfusion and brain structure in patients with major depression: a multimodal magnetic resonance imaging study. *J Psychiatry Neurosci* 40:412-421.
- Verstynen TD, Weinstein AM, Schneider WW, Jakicic JM, Rofey DL, Erickson KI. 2012. Increased body mass index is associated with a global and distributed decrease in white matter microstructural integrity. *Psychosom Med* 74:682-690.
- Viola S, Viola P, Buongarzone MP, Fiorelli L, Mattucci F, Litterio P. 2014. New brain reperfusion rehabilitation therapy improves cognitive impairment in mild Alzheimer's disease: a prospective, controlled, open-label 12-month study with NIRS correlates. *Aging Clin Exp Res* 26:417-425.
- Volkow ND, Wang GJ, Franceschi D, Fowler JS, Thanos PP, Maynard L, Gatley SJ, Wong C, Veech RL, Kunos G, Kai Li T. 2006. Low doses of alcohol substantially decrease glucose metabolism in the human brain. *Neuroimage* 29:295–301.
- Walhovd KB, Westlye LT, Amlie I, Espeseth T, Reinvang I, Raz N, Agartz I, Salat DH, Greve DN, Fischl B, Dale AM, Fjell AM. 2011. Consistent neuroanatomical age-related volume differences across multiple samples. *Neurobiol Aging* 32:916-932.
- Walker KR., Tesco G. 2013. Molecular mechanisms of cognitive dysfunction following traumatic brain injury. *Front Aging Neurosci* 5:29.
- Wan Q, Liu Y, Guan Q, Gao L, Lee KO, Zhao J. 2005. Ethanol feeding impairs insulin-stimulated glucose uptake in isolated rat skeletal muscle: role of Gs alpha and cAMP. *Alcohol Clin Exp Res* 29:1450-1456.
- Wang F, Guo X, Shen X, Kream RM, Mantione KJ, Stefano GB. 2014. Vascular dysfunction associated with type 2 diabetes and Alzheimer's disease: a potential etiological linkage. *Med Sci Monit Basic Res* 20:118-129.
- Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F, McKeon F, Bobo T, Franke TF, Reed JC. 1999. Ca²⁺-Induced Apoptosis Through Calcineurin Dephosphorylation of BAD. *Science* 284: 339–343.
- Wang J, Bai X, Chen Y, Zhao Y, Liu X. 2012. Homocysteine Induces Apoptosis of Rat Hippocampal Neurons by Inhibiting 14-3-3 ϵ Expression and Activating Calcineurin. *PLoS One* 7: e48247.
- Wang Y, Zhang H, Tang S, Liu X, O'Neil A, Turner A, Chai F, Chen F, Berk M. 2014. Assessing regional cerebral blood flow in depression using 320-slice computed tomography. *PLoS One* 9:e107735.
- Ward MA, Carlsson CM, Trivedi MA, Sager MA, Johnson SC. 2005. The effect of body mass index on global brain volume in middle-aged adults: a cross sectional study. *BMC Neurol* 5, 23.
- Watanabe T, Zhang N, Liu M, Tanaka R, Mizuno Y, Urabe T. 2006. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. *Stroke* 37:1539-1545.
- Weller RO, Boche D, Nicoll JA. 2009. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. *Acta Neuropathol* 118:87-102.
- Wes PD, Easton A, Corradi J, Barten DM, Devizde N, DeCarr LB, Truong A, He A, Barrezueta NX, Polson C, Bourin C, Flynn ME, Keenan S, Lidge R, Meredith J, Natale J, Sankaranarayanan S, Cadelina GW, Albright CF, Cacace AM. 2014. Tau overexpression impacts neuroinflammation gene expression network perturbed in Alzheimer's disease. *PLoS One* 9:e106050.
- Whitehouse PJ, Sciuilli CG, Mason RM. 1997. Dementia drug development: use of information systems to harmonize global drug development. *Psychopharmacol Bull* 33:129–133.
- Wilkes JJ, Nagy LE. 1996. Chronic ethanol feeding impairs glucose tolerance but does not produce skeletal muscle insulin resistance in rat epitrochlearis muscle. *Alcohol Clin Exp Res* 20:1016-1022.

- Willette AA, Bendlin BB, Starks EJ, Birdsill AC, Johnson SC, Christian BT, Okonkwo OC, La Rue A, Hermann BP, Kosciak RL, Jonaitis EM, Sager MA, Asthana S. 2015. Association of Insulin Resistance with Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease. *JAMA Neurol* 72:1013-1020.
- Willette AA, Xu G, Johnson SC, Birdsill AC, Jonaitis EM. 2013. Insulin resistance, brain atrophy and cognitive performance in late middle-aged adults. *Diabetes Care* 36:443-449.
- Williams BL, Lipkin WI. 2006. Endoplasmic reticulum stress and neurodegeneration in rats neonatally infected with Borna disease virus. *J Virol* 80:8613-8626.
- Wirth M, Villeneuve S, Haase CM, Madison CM, Oh H, Landau SM, Rabinovici GD, Jagust WJ. 2013. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. *JAMA Neurol* 70:1512-1519.
- Wolters M, Ströhle A, Hahn A. 2004. Age-associated changes in the metabolism of vitamin B(12) and folic acid: prevalence, aetiopathogenesis and pathophysiological consequences. *Z Gerontol Geriatr* 37:109-135.
- Won JS, Kim J, Annamalai B, Shunmugavel A, Singh I, Singh AK. 2013. Protective role of S-nitrosoglutathione (GSNO) against cognitive impairment in rat model of chronic cerebral hypoperfusion. *J Alzheimers Dis* 34:621-635.
- Won JS, Annamalai B, Choi S, Singh I, Singh AK. 2015. S-nitrosoglutathione reduces tau hyperphosphorylation and provides neuroprotection in rat model of chronic cerebral hypoperfusion. *Brain Res* 1624:359-69.
- Wright JW, Masino AJ, Reichert JR, Turner GD, Meighan SE, Meighan PC, Harding JW. 2003. Ethanol-induced impairment of spatial memory and brain matrix metalloproteinases. *Brain Res* 963:252-261.
- Wu J, Li H, Sun X, Zhang H, Hao S, Ji M, Yang J, Li K. 2015. A Mitochondrion-Targeted Antioxidant Ameliorates Isoflurane-Induced Cognitive Deficits in Aging Mice. *PLoS One* 10:e0138256.
- Wyss-Coray T, Lin C, von Euw D, Masliah E, Mucke L, Lacombe P. 2000. Alzheimer's disease-like cerebrovascular pathology in transforming growth factor-beta 1 transgenic mice and functional metabolic correlates. *Ann N Y Acad Sci* 903:317-323.
- Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G. 2013. Prevalence and control of diabetes in Chinese adults. *JAMA* 310:948-959.
- Yacoubian TA, Slone SR, Harrington AJ, Hamamichi S, Schieltz JM, Caldwell KA, Caldwell GA, Standaert DG. 2010. Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease. *Cell Death Dis* 1: e2.
- Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tykavsky FA, Newman AB. 2004. The metabolic syndrome, inflammation, and risk of cognitive decline. *JAMA* 292:2237-2242.
- Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. 2005. Obstructive sleep apnea as a risk factor for stroke and death. *N Engl J Med* 353:2034-2041.
- Yamamoto K, Hayakawa T, Mogami H, Akai F, Yanagihara T. 1990. Ultrastructural investigation of the CA1 region of the hippocampus after transient cerebral ischemia in gerbils. *Acta Neuropathol* 80:487-492.
- Yang Y, Zhang J, Liu H, Wang J, Xin J, Deng M. 2013. Changes in Levels of Hypoxia-Induced Mediators in Rat Hippocampus During Chronic Cerebral Hypoperfusion. *Neurochem Res* 38: 2433-2439.
- Yarchoan M, Xie SX, Kling MA, Toledo JB, Wolk DA, Lee EB, Van Deerlin V, Lee VM, Trojanowski JQ, Arnold SE. 2012. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. *Brain* 135:3749-3756.
- Yuen N, Anderson SE, Glaser N, Tancredi DJ, O'Donnell ME. 2008. Cerebral blood flow and cerebral edema in rats with diabetic ketoacidosis. *Diabetes* 57:2588-2594.
- Zerbi V, Jansen D, Wiesmann M, Fang X, Broersen LM, Veltien A, Heerschap A, Kiliaan AJ. 2014. Multinutrient diets improve cerebral perfusion and neuroprotection in a murine model of Alzheimer's disease. *Neurobiol Aging* 35:600-613.

- Zhang P, Li W, Li L, Wang N, Li X, Gao M, Zheng J, Lei S, Chen X, Lu H, Liu Y. 2012. Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury. *Neuroscience* 201:297-306.
- Zhao K, Ippolito G, Wang L, Price V, Kim MH, Cornwell G, Fulenchek S, Breen GA, Goux WJ, D'Mello SR. 2010. Neuron-selective toxicity of tau peptide in a cell culture model of neurodegenerative tauopathy: essential role for aggregation in neurotoxicity. *J Neurosci Res* 88:3399-3413.
- Zhao Q, Xiong Y, Ding D, Guo Q, Hong Z. 2012. Synergistic Effect between Apolipoprotein E ϵ 4 and Diabetes Mellitus for Dementia: Result from a Population-Based Study in Urban China. *J Alzheimers Dis* 32:1019-1027.
- Zhao YN, Wang F, Fan YX, Ping GF, Yang JY, Wu CF. 2013. Activated microglia are implicated in cognitive deficits, neuronal death, and successful recovery following intermittent ethanol exposure. *Behav Brain Res* 236:270-282.
- Zhou J, Austin RC. 2009. Contributions of hyperhomocysteinemia to atherosclerosis: Causal relationship and potential mechanisms. *Biofactors* 35:120-129.
- Zielinski MR, Kim Y, Karpova SA, McCarley RW, Strecker RE, Gerashchenko D. 2014. Chronic sleep restriction elevates brain interleukin-1 beta and tumor necrosis factor-alpha and attenuates brain-derived neurotrophic factor expression. *Neurosci Lett* 580:27-31.

////////////////////////////////////

Table 1.

Conditions That Promote Cerebral Hypoperfusion and Glucose Hypometabolism:**Pathophysiological Ramification**

Risk	Factors	Implications for Vulnerability
Aging	Multi-factorial mechanisms unhealthy diet, dysfunctional breathing, sleep restriction, and excess consumption of alcohol	Vascular pathology and cortical microinfarcts (Kövari et al., 2004; 2007), gray matter lacunes (Gold et al., 2005), and irreversible endothelial dysfunction (Hallam et al., 2010; Thal et al., 2009).
Obstructive Sleep Apnea	Nocturnal apneas/hypopnea	Cerebral hypoperfusion - Decreased CBF velocity and delayed cerebrovascular compensation (Bålfors and Franklin, 1994; Baril et al., 2015; Corfield and Meadows, 2006).
Hypertension	Vascular inflammation, BBB disruption, hypoperfusion, and ischemia	Changes in blood vessel wall, hypoperfusion, and a decrease in cortical thickness; brain volume reduction (Shah et al., 2012, Beauchet et al., 2013; Alosco et al., 2013; Kruyer et al., 2015; Van Der Gucht et al., 2015).
Obesity/Metabolic Syndrome	Dyslipidemia, and glucose/insulin dysregulation, diabetes	Hyperlipidemia disrupts endothelial and smooth muscle function; vasoconstriction in the cerebral vasculature, and oxidative stress (Osmond et al., 2009). Decreased NO and CBF (Ayata et al., 2013; Toda et al., 2014).
Vitamin B12/Folate Deficiency	Hyperhomocysteinemia, microvasculature pathology	Proatherogenic, pro-inflammatory, increases CVD, increased matrix metalloproteinases, RAGE, apoptosis (Akchiche et al., 2012; Narayan et al., 2011; da Cunha et al., 2012; Shiran et al., 2015; Hofmann et al., 2001; Madsen et al., 2015)
Diabetes	Dysglycemia, insulin resistance	Increased C-reactive protein, inflammatory markers, and reduced CBF (Anstey et al., 2015; Biessels et al., 2014; Cherbuin et al., 2012; Kerti et al., 2013; Willette et al., 2013; Novak et al., 2006; Fukazawa et al., 2013; Kwon et al., 2015).
Depression	Lower CBF	Decreased arterial Pulsatility and reduced blood flow in several brain regions including PFC (Nagafusa et al., 2012; Ota et al., 2014; Uemura et al., 2014; Wang et al., 2014).
Traumatic Brain Injury	edema, excitotoxicity, loss of neuronal and glial integrity, dysfunctional mitochondrial	Upregulates axonal damage and A β 42 production, and down- regulates long-term potentiation

	bioenergetics, oxidative stress, inflammation, and cell membrane disruption	(Walker and Tesco, 2013; Fakhran et al., 2013). Decreased CBF, brain hypoperfusion, glucose hypometabolism, and diminished energy supply (Olesen et al., 1981; Golding et al., 1999; Ayata et al., 2004; Parkin et al., 2005; Lauritzen et al., 2011; Romero et al., 2014).
--	---	---

Accepted Article

180x156mm (96 x 96 DPI)

Accepted

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Daulatzai, MA

Title:

Cerebral Hypoperfusion and Glucose Hypometabolism: Key Pathophysiological Modulators Promote Neurodegeneration, Cognitive Impairment, and Alzheimer's Disease

Date:

2017-04-01

Citation:

Daulatzai, M. A. (2017). Cerebral Hypoperfusion and Glucose Hypometabolism: Key Pathophysiological Modulators Promote Neurodegeneration, Cognitive Impairment, and Alzheimer's Disease. JOURNAL OF NEUROSCIENCE RESEARCH, 95 (4), pp.943-972.
<https://doi.org/10.1002/jnr.23777>.

Persistent Link:

<http://hdl.handle.net/11343/291455>